References
Where each of epiClinical's numbers comes from, and every work the evidence review drew on, chapter by chapter.
Where each number comes from
Evidence-anchored Direction from evidence Illustrative
Therapeutic-area baselines (6)
| Number | Value | Source |
|---|---|---|
| Oncology | 0.35 patients per site per month | Inside published ranges: IQVIA medians 0.1 to 0.2, industry Phase III mean 0.80 in oncology (D01) |
| Cardiovascular | 0.3 patients per site per month | CV trials analysis (Khan et al. 2025, JAMA Cardiology): 0.3 patients/site/month overall, US 0.2 |
| CNS and psychiatry | 0.45 patients per site per month | No per-site rate by therapeutic area was found; value sits inside the all-area range (D01) |
| Immunology and GI | 0.3 patients per site per month | No per-site rate by therapeutic area was found; value sits inside the all-area range (D01) |
| Respiratory | 0.4 patients per site per month | No per-site rate by therapeutic area was found; value sits inside the all-area range (D01) |
| Rare disease | 0.1 patients per site per month | Rare-disease trials recruit far fewer patients per site; value sits inside published ranges (D01) |
Country multipliers (6)
| Number | Value | Source |
|---|---|---|
| United States | ×0.75 | Site-productivity index: US sites yield 0.76 to 0.77 of the study average (D03). Khan et al. found 0.2 against 0.3 overall in cardiovascular trials; in oncology IQVIA reports US sites ahead of European ones |
| United Kingdom | ×0.85 | Site-productivity index (D04). The UK is the only country with measured public-trial rates (0.92 to 0.95 per centre per month); commercial recruitment fell 44% from 2017/18 to 2021/22 |
| Spain | ×1 | Spanish sites yield 75 to 90% of the study average and IQVIA's oncology median matches the UK and Germany (D05). Spain's real advantage is start-up speed: 231 days from submission to first dose (2022) (INFARMA 2021) |
| Poland | ×1.4 | Site-productivity index: Polish sites yield 148 to 167% of the study average (D06); growth has stalled since 2022 |
| Turkey | ×1 | No current per-site rate exists (D08). The only index (2006 to 2008) put Turkey at 0.70 of average, and IQVIA's recruitment score ranks it below Poland and Spain |
| India | ×1.1 | India matched the US per site in FDA's FY2008 inspections and reached about 17 per site against Poland's 22 in EMA 2005 to 2009 data, which implies about ×1.08 (D07; range 1.0 to 1.3) |
Site multipliers (17)
| Number | Value | Source |
|---|---|---|
| Site type: Academic hospital | ×1 | Reference category |
| Site type: Dedicated research centre | ×1.25 | Research-focused sites recruited 41% better in a 72-protocol analysis; range 1.2 to 1.3 (D10) |
| Site type: Community hospital | ×0.85 | UK GP sites 0.52 to 0.71 against hospital 0.90 to 1.22 per centre per month2; US community enrolment 7.0% of patients against 15.9% at academic centres (D10) |
| Site type: Private practice | ×0.75 | Independent practices recruit below hospital sites; range 0.7 to 0.75 (D10) |
| Track record: Average | ×1 | Reference category |
| Track record: Top-quartile enroller | ×1.4 | A site's record predicts its next trial only weakly (correlation 0.13 to 0.16, up to 0.46 with patient-volume data), so the selection effect is smaller than the spread of outcomes (D11) |
| Track record: New site, no history | ×0.75 | epiClinical assumption |
| Track record: Previously under-enrolled | ×0.5 | Past enrolment predicts future enrolment weakly; plausible range 0.5 to 0.6 (D11) |
| Protocol & population: Standard | ×1 | Reference category |
| Protocol & population: Second line | ×0.6 | Real-world attrition between treatment lines is 40 to 60% in lung cancer23 (D14) |
| Protocol & population: Third line or later | ×0.4 | Attrition compounds at each line, so the eligible pool shrinks faster than one rate ratio implies (D14) |
| Protocol & population: Rare orphan population | ×0.73 | Accrual in trials behind FDA cancer approvals (2024): Poisson adjusted rate ratio 0.73 against non-orphan. Never combined with the rare-disease baseline (D16) |
| Competing trials: A few | ×1 | Reference category |
| Competing trials: None | ×1.1 | epiClinical assumption |
| Competing trials: Heavy competition | ×0.75 | Applies when the eligible pool is scarce: low-accrual odds rose 1.88 times per extra competing trial per 10,000 eligible patients a year (787 NCI trials); no effect when patients were plentiful (D12) |
| Protocol & population: Moderately restrictive eligibility | ×0.8 | One or two non-essential exclusions. Three common lung-cancer exclusions cut the eligible pool from 98.5% to 52.3% (Harvey 2021) (D13) |
| Protocol & population: Highly restrictive eligibility | ×0.55 | Three or more non-essential exclusions; more criteria independently predict accrual failure (Carlisle 2015) (D13) |
Planner parameters (34)
| Number | Value | Source |
|---|---|---|
| Site-to-site variation | 1 coefficient of variation | Fitted gamma shapes of 1.2 to 2.3 in real trials (Minois et al. 2017; Bakhshi 2011, median shape 1.43); Anisimov's planning examples use 1.2 |
| Site-to-site variation, lower | 1 coefficient of variation | IFM myeloma trials, gamma shape 1.75 to 2.15 (Minois et al., Statistics in Medicine 2017) |
| Site-to-site variation, upper | 1 coefficient of variation | Anisimov and Austin 2022: the 'medium variation' planning setting |
| First site opens, United States | 4 months | First US site activated a median 124 days after final protocol approval (Friends of Cancer Research, pivotal oncology trials 2020 to 2025) |
| Last site opens, United States | 10 months | US took 309 days to activate 75% of planned sites (Friends of Cancer Research 2026) |
| First site opens, United Kingdom | 4 months | Median 122 days from application to first participant, commercial CTIMPs, April to September 2025 (UK clinical research delivery KPIs) |
| Last site opens, United Kingdom | 10 months | epiClinical assumption: sites open over six months after the first |
| First site opens, Spain | 8 months | Median 231 days from submission to first dose, 2022 (IQVIA for EFPIA 2024) |
| Last site opens, Spain | 14 months | epiClinical assumption: sites open over six months after the first |
| First site opens, Poland | 11 months | EEA oncology site start-up averages 339 days (IQVIA for EFPIA 2024); no Poland-specific median found |
| Last site opens, Poland | 17 months | epiClinical assumption: sites open over six months after the first |
| First site opens, Turkey | 6 months | No median found; statutory clocks are 12 business days for ethics and 22 for TİTCK, plus contracting |
| Last site opens, Turkey | 12 months | epiClinical assumption: sites open over six months after the first |
| First site opens, India | 6 months | Statutory chain: CDSCO 90 working days with ethics review in parallel, a 5 to 6 month planning assumption (NDCT Rules 2019) |
| Last site opens, India | 12 months | epiClinical assumption: sites open over six months after the first |
| Most sites a country can supply, United States | 100 sites | 1,500 × share of global active industry sites (32.1%, LongTaal 2024), capped at 100; the scale is an assumption chosen so the portfolio studies fit |
| Most sites a country can supply, United Kingdom | 44 sites | 1,500 × share of global active industry sites (2.9%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit |
| Most sites a country can supply, Spain | 71 sites | 1,500 × share of global active industry sites (4.7%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit |
| Most sites a country can supply, Poland | 41 sites | 1,500 × share of global active industry sites (2.7%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit |
| Most sites a country can supply, Turkey | 18 sites | 1,500 × share of global active industry sites (1.2%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit |
| Most sites a country can supply, India | 15 sites | 1,500 × share of global active industry sites (1%, LongTaal 2024); the scale is an assumption chosen so the portfolio studies fit |
| Sites per country, by default | 6 sites | Median 64 sites per industry Phase III trial (PLOS ONE 2022) across about 11 countries (Tufts CSDD 2012) |
| Screen failure, overall | 36.3% | Tufts CSDD 2019: 76 Phase II and III trials completed 2016 to 2019 |
| Screen failure, Oncology | 40% | 34% across 269 trials (UCSD 2013 to 2021) and 51% across 15 RCTs (Tata Memorial 2023) |
| Screen failure, Cardiovascular | 45% | Heart failure outcome trials: DAPA-HF 42%, EMPEROR-Reduced 48% |
| Screen failure, CNS and psychiatry | 57% | Tufts CSDD 2019: CNS screen failure 57% |
| Screen failure, Immunology and GI | 48% | Inflammatory bowel disease trials: ulcerative colitis 43%, Crohn's disease 53% (17 trials, 16,913 screened, 2025) |
| Screen failure, Respiratory | 40% | COPD Phase III trials: 37% to 42% screened but not randomised |
| Screen failure, Rare disease | 56% | Tufts CSDD 2019: 56% of rare-disease volunteers not randomised |
| Drop-out | 15% | Median 11% across 10,252 Phase III trials (Chen et al. 2025) to 19.1% (Tufts CSDD 2019) |
| Drop-out, CNS and psychiatry | 25.9% | Tufts CSDD 2019: CNS drop-out 25.9% |
| Confidence wanted, by default | 85% | JMP Clinical's default; 0.8 and 0.9 are the common alternatives (Anisimov and Austin 2022) |
| Uncertainty in the rates themselves | 0 coefficient of variation | epiClinical assumption: the mean rate is itself an estimate; without this, bands are too narrow (Mountain and Sherlock 2022) |
| Simulated studies per forecast | 10,000 simulated studies | 10,000 runs as in JMP Clinical and Anisimov and Oliver 2024 |
Monitoring rules (22)
| Number | Value | Source |
|---|---|---|
| Inner funnel limit: outside it is worth watching | 1 two-sided confidence | Funnel plots for comparing institutional performance use 95% and 99.8% limits, roughly two and three standard deviations (Spiegelhalter 2005, Statistics in Medicine) |
| Outer funnel limit: outside it is an alarm | 1 two-sided confidence | Funnel plots for comparing institutional performance use 95% and 99.8% limits, roughly two and three standard deviations (Spiegelhalter 2005, Statistics in Medicine) |
| Nothing randomised although at least this many patients were expected | 3 patients expected | epiClinical assumption: a simple operational trigger of the kind CROs use to start a conversation with a site. With typical site-to-site spread, about one ordinary site in five with three patients expected still has none, so it prompts a call, not a judgement |
| A study whose first patient comes this many months after its first site opened is flagged | 2 months | Trials slower than 70 days to first patient became slow accruers 23% of the time against 5% (MD Anderson, 4,269 trials); NCI trials whose first patient came after two months were less likely to reach minimum accrual. Both cut-offs come from splitting historical data, not a validated standard (review note 02) |
| A site is overdue for its first patient when fewer than this share of similar sites would still be waiting | 10% | epiClinical assumption, using the planner model: each site waits according to its own expected rate and the spread of site rates (coefficient of variation 0.9) |
| Sites active as a share of plan, below which activation is flagged | 80% | epiClinical assumption; trials with too few sites are more likely to fail on accrual (review note 02) |
| Enrolment as a share of the expected count, below which it is flagged | 80% | epiClinical assumption |
| Enrolment as a share of the expected count, below which it is outside the acceptable range | 60% | NCI trials under 60% of target at the planned end rarely recovered (odds ratio 0.19; review note 02) |
| Planned sites as a share of the countries' site caps, above which the plan is stretched | 80% | epiClinical assumption; plans needing a large share of the available pool are more likely to under-accrue (Bennette, review note 02) |
| Patients needed before a QTL is judged | 50 patients | epiClinical assumption: QTL rates are unstable with few patients, and many early breaches in vendor data were noise (review note 01) |
| A site that has recruited below this share of its expected count is behind | 75% | epiClinical assumption, between the enrolment flag (0.8) and the point NCI trials rarely recovered from (0.6); about half of sites fall short of plan in practice (11% enrol nobody, 37% under-enrol; Tufts, register S-01) |
| A site that has recruited above this share of its expected count is ahead | 125% | epiClinical assumption, set symmetrically to the behind line on a ratio scale (1 ÷ 0.8) |
| Patients a site must have been expected to recruit before it is judged | 2 patients expected | epiClinical assumption: below this, a site's count says more about chance than about the site |
| Patients offered a trial who agree to take part | 55% | 55.0% of patients offered a cancer treatment trial agreed, across 35 studies (Unger 2021, JNCI, https://doi.org/10.1093/jnci/djaa155) |
| Patients needed at a funnel stage before a site's rate there is compared with the study's | 8 patients | epiClinical assumption: with fewer, a single patient moves the rate by more than ten points |
| A site's rate at a funnel stage is out of line when so poor a rate would happen by chance less often than this | 10% | epiClinical assumption: a loose screen, because it prompts a look at the screening log rather than a judgement |
| Power each study is assumed to be designed for | 80% | Conventional design value; the fictional studies do not state their power |
| Two-sided significance level each study is assumed to use | 5% | Conventional design value; the fictional studies do not state it |
| Power below which a QTL breach is critical and escalated to the sponsor | 70% | epiClinical assumption: a study designed for 80% power that falls to 70% has lost a third of its margin against a false negative |
| A study whose forecast finish is this many months past the sponsor’s deadline is red; any slip past the deadline is amber | 6 months | epiClinical assumption: any forecast past the deadline needs a recovery plan, and six months late needs the sponsor’s decision on scope or timelines |
| Share of sites with data over at least one KRI threshold at which a study is amber | 10% | epiClinical assumption, to be tuned against which flagged sites went on to need a triggered visit |
| Share of sites with data over at least one KRI threshold at which a study is red | 20% | epiClinical assumption, as for the amber share |
Key risk indicators (8)
| Number | Value | Source |
|---|---|---|
| Site activation overdue | Over 30 days | epiClinical assumption: a month's grace before a late site is escalated |
| Screen failure above the study's | Over +15 points | epiClinical assumption; screen failure varies widely by therapeutic area (register PM-05), so sites are compared with their own study |
| Data entry lag | Over 7 days | Common sponsor convention of five working days; no sourced difference between the study countries was found, so every country uses the default |
| Queries open over 30 days | Over 20% | epiClinical assumption; TransCelerate lists query ageing among indicators of site data quality, without a standard limit |
| Important protocol deviations | Over 2 | epiClinical assumption; complex protocols and new sites produce more deviations (register S-24, S-05) |
| Consent findings | Over 5 | epiClinical assumption; consent documents grow longer and harder to complete (register PD-16) |
| Study drug at the site | Under 4 weeks | epiClinical assumption; read from the randomisation and supply system, which the synthetic data does not include |
| Enrolment against the diversity plan | Under 80% | FDORA 2022 introduced diversity action plans for Phase III studies in the US, though FDA's guidance on them has been in flux since 2025; racial and ethnic groups are under-represented in US trials (register PB-12). The 80% line is an epiClinical assumption |
Quality tolerance limits (12)
| Number | Value | Source |
|---|---|---|
| Missing primary endpoint data | Grade A | Missing outcome data can overturn up to a third of significant results (Akl 2012); losses exceeded the fragility index in 53% of 399 trials (Walsh 2014) |
| Missing primary endpoint data: benchmark | 7.9% | TransCelerate QTL benchmark survey: median 7.9% across sponsors (review note 01) |
| Missing primary endpoint data: limit | The study's drop-out assumption | The acceptable range is the drop-out the study's power calculation allowed for (planner parameters, D24); the early-warning line sits at two-thirds of it |
| Lost to follow-up or withdrew consent | Grade A | The same missing-data mechanism as missing endpoint data, held tighter than treatment discontinuation (review note 01) |
| Lost to follow-up or withdrew consent: benchmark | 3.7% | TransCelerate medians: 0.8% lost to follow-up and 2.9% withdrawal of consent (review note 01) |
| Lost to follow-up or withdrew consent: limit | 6% | epiClinical assumption: above the combined benchmark median of 3.7% and in line with published case studies that set limits around 4% for unknown survival status |
| Stopped study treatment early | Grade B | The most widely reported QTL parameter; no study links it directly to trial failure (review note 01) (Makowski 2021) |
| Stopped study treatment early: benchmark | 10.7% | TransCelerate median 10.7%; Phase III 11.5% (review note 01) |
| Stopped study treatment early: limit | 15% | epiClinical assumption: above the Phase III benchmark of 11.5%; a breach dilutes the treatment effect and reduces power |
| Ineligible patients randomised | Grade B | The most common randomisation error; it dilutes the effect in the intended population (review note 01) (Yelland 2018) |
| Ineligible patients randomised: benchmark | 3.2% | TransCelerate median 3.2% (review note 01) |
| Ineligible patients randomised: limit | 5% | epiClinical assumption: above the 3.2% median; eligibility errors were reported in 39% of 82 trials |
Shock multipliers (30)
| Number | Value | Source |
|---|---|---|
| Pandemic peak (April 2020), United States | ×0.55 | New patients per site 45% below the 2019 baseline in April 2020, read from Medidata’s chart; the same release’s year-on-year table says −83%, so the size is less certain than the UK and India figures (Medidata Release 9.0; D37). |
| Pandemic peak (April 2020), United Kingdom | ×0.13 | Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: UK −87% in April |
| Pandemic peak (April 2020), Spain | ×0.4 | New patients per site 60% below the 2019 baseline in April 2020, read from Medidata’s chart; the year-on-year table says −82% (Medidata Release 9.0; D37). |
| Pandemic peak (April 2020), Poland | ×0.4 | epiClinical assumption for the peak |
| Pandemic peak (April 2020), Turkey | ×0.35 | epiClinical assumption for the peak |
| Pandemic peak (April 2020), India | ×0.02 | Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: India −98% in April |
| Pandemic recovery (August 2020), United States | ×0.78 | New patients per site 22% below the 2019 baseline in August 2020, read from Medidata’s chart (Medidata Release 9.0; D37). |
| Pandemic recovery (August 2020), United Kingdom | ×0.6 | Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: UK −40% in August |
| Pandemic recovery (August 2020), Spain | ×0.65 | epiClinical assumption for recovery: two readings of Medidata’s August figure for Spain disagree (+25% and −34%), so it cannot be anchored yet (D37). |
| Pandemic recovery (August 2020), Poland | ×0.7 | epiClinical assumption for recovery |
| Pandemic recovery (August 2020), Turkey | ×0.65 | epiClinical assumption for recovery |
| Pandemic recovery (August 2020), India | ×0.29 | Medidata COVID-19 analyses (2020): new patients per site vs pre-COVID baseline: India −71% in August |
| Border conflict: site near the border, United States | ×1 | Not affected by this scenario |
| Border conflict: site near the border, United Kingdom | ×1 | Not affected by this scenario |
| Border conflict: site near the border, Spain | ×1 | Not affected by this scenario |
| Border conflict: site near the border, Poland | ×1 | Not affected by this scenario |
| Border conflict: site near the border, Turkey | ×0.3 | Sites near a conflict border lose most of their patient flow. The direction is supported by Ukraine, where effects concentrated in the east and north; the size is an assumption (Clinical Research News 2022; D39). |
| Border conflict: site near the border, India | ×1 | Not affected by this scenario |
| Border conflict: site elsewhere in country, United States | ×1 | Not affected by this scenario |
| Border conflict: site elsewhere in country, United Kingdom | ×1 | Not affected by this scenario |
| Border conflict: site elsewhere in country, Spain | ×1 | Not affected by this scenario |
| Border conflict: site elsewhere in country, Poland | ×1 | Not affected by this scenario |
| Border conflict: site elsewhere in country, Turkey | ×0.9 | The same conflict barely touches distant sites: about half of Ukraine’s sites kept recruiting. The direction is supported; the size is an assumption (Phesi 2022; D39). |
| Border conflict: site elsewhere in country, India | ×1 | Not affected by this scenario |
| Regional war next door (2022 analogue), United States | ×1 | Not affected by this scenario |
| Regional war next door (2022 analogue), United Kingdom | ×1 | Not affected by this scenario |
| Regional war next door (2022 analogue), Spain | ×1 | Not affected by this scenario |
| Regional war next door (2022 analogue), Poland | ×1.1 | The sign is supported: Poland’s recruiting sites rose 10% in 2022 while Ukraine’s fell 48% (Phesi via Lab News 2022). The size is an assumption, and no gain in trials or in each site’s productivity was measured (D38). |
| Regional war next door (2022 analogue), Turkey | ×1 | Not affected by this scenario |
| Regional war next door (2022 analogue), India | ×1 | Not affected by this scenario |
Shock profiles (27)
| Number | Value | Source |
|---|---|---|
| Pandemic wave: depth (a lower rate at the sites that stay open) | 65% | New patients per site fell 65% worldwide; in April 2020 the fall was 41% in oncology, 65% in CNS, 92% in respiratory and 97% in cardiovascular trials. Areas without a figure take the overall 65% (Medidata Release 9.0; D30). |
| Pandemic wave: sites in reach | From the study's sites | Every country in Medidata’s series was hit, so every site is in reach (Medidata Release 6.0; D30). |
| Pandemic wave: timing | 2 months, 5 to recover | Two months at the bottom and five to recover in Medidata’s global series. Industry protocols were still 31% to 66% down by area in 2021 and the UK regained 2019 levels only in September 2021, hence the long-tail option of 12 to 18 months, drawn at 15 (Medidata Release 9.0; McDonald et al. 2022; D30). |
| Regional war: depth (recruiting sites lost) | 48% | Ukraine had 48% fewer recruiting sites seven months into the war and 62% fewer at 13 months, with no recovery (Phesi via Lab News 2022 and 2023; D31). |
| Regional war: sites in reach | From the study's sites | Every site the study has in the country at war is in reach; the share comes from the study’s own site list (D31, D36). |
| Regional war: timing | 13 months, 30 to recover | Thirteen months or more at the bottom and 24 to 36 to recover, drawn at 30: sponsors stayed away for about three years (Clinical Leader 2026; D31). |
| Border conflict: depth (a lower rate, steepest at the sites near the border) | 70% | A fall of 70% near the border and 10% elsewhere in the country, with up to a third of enrolled participants near the border lost to follow-up. The gradient is supported, since about half of Ukraine’s sites kept recruiting while effects concentrated in the east and north; the sizes are assumptions (Phesi 2022; Clinical Research News 2022; D32, D39). |
| Border conflict: sites in reach | From the study's sites | The sites near the border come from the study’s own site list (D32, D36). |
| Border conflict: timing | 6 months, 6 to recover | Six months at the bottom and six to recover are epiClinical assumptions (D32). |
| Public funding cut: depth (staff and capacity lost at the sites hit) | 20% | An industry study is hit second-hand, through its academic sites: sites hit by NIH cuts froze hiring (32%) and cut staff (25%) (WCG 2025; D33). The loss of capacity is an assumption. For a publicly funded trial the direct risk was measured: 3.5% of NIH-funded trials lost funding (383 of 11,008), 14.4% in infectious disease, with more than 74,000 participants affected (Patel et al. 2025). |
| Public funding cut: sites in reach | 46% | In a survey of 611 sites in 2025, 46% had been hit by NIH cuts or industry trial pauses, larger sites far more often (WCG 2025; D33). |
| Public funding cut: timing | 36 months, 0 to recover | Until grants are restored or trials close; how long that takes is not measured (D33). |
| Protocol amendment: depth (a slower rate while the amendment is put in place, and later openings for sites not yet open) | 10% | Amended protocols recruit for longer and enrol fewer patients than planned, but no study measured the fall in rate; 10% is an epiClinical assumption (Getz 2016; D34). |
| Protocol amendment: sites in reach | From the study's sites | Every site takes the amendment; 57% to 76% of protocols have at least one (Getz 2016; Getz 2024; D34). |
| Protocol amendment: timing | 9 months, 0 to recover | About 260 days to put a substantial amendment in place (Getz 2024; D34). |
| Seasonality: depth (a rate that dips at the holidays) | 10% | Recruitment dips by about a tenth in December and January and in July and August; the other months are set so the year averages out (Haidich and Ioannidis 2001; Webster et al. 2015; D34). |
| Seasonality: sites in reach | From the study's sites | Every site follows the same calendar (D34). |
| Seasonality: timing | 0 months, 0 to recover | The pattern repeats every year (D34). |
| Regulatory shock: depth (new approvals and running trials held while the rules change) | 71% | After India’s Supreme Court ruling, trial approvals fell from 253 in 2012 to 73 in 2013, a fall of 71% (Nair 2015; D34). |
| Regulatory shock: sites in reach | From the study's sites | Every site in the country is in reach: the ruling held approved trials as well as new ones (Nair 2015; D34). |
| Regulatory shock: timing | 12 months, 12 to recover | About a year for the new rules to take hold is an epiClinical reading of the India case; the recovery is an assumption (D34, D43). |
| Drug shortage: depth (a lower rate at the sites short of the drug) | 50% | How far enrolment fell at the centres that cut it is not measured; half is an epiClinical assumption (D34). |
| Drug shortage: sites in reach | 58% | In 2023, 174 of 608 NCI trials were flagged as hit by cancer drug shortages, and 58% of affected centres reduced enrolment (CNN 2023; The ASCO Post 2024; D34). |
| Drug shortage: timing | 6 months, 6 to recover | Six months short and six to recover are epiClinical assumptions; shortages in the survey lasted months (The ASCO Post 2024; D34). |
| Earthquake: depth (sites in the disaster zone stop recruiting) | 90% | Sites in the provinces hit lose almost all their patient flow while hospitals are damaged or overwhelmed; the size is an assumption, the direction is not (IFRC 2023; D34). |
| Earthquake: sites in reach | From the study's sites | The sites in the provinces hit by the 2023 earthquakes come from the study’s own site list; the regulator’s response, letting patients move to other sites and visits happen remotely, is the playbook to follow (TİTCK 2023; D34). |
| Earthquake: timing | 2 months, 6 to recover | Two months stopped and six to recover are epiClinical assumptions (D34, D45). |
Rescue sites (7)
| Number | Value | Source |
|---|---|---|
| Rescue is called when enrolment falls below this share of plan at a quarterly milestone | 0.6 | Trials below 60% of their target rarely recovered, and an early decision is what makes a rescue work (Cheng 2011; Schroen 2010; D20). |
| A rescue site recruits at this share of the study’s own sites in the country | 0.6 | Between 0.5 and 0.75 of the base rate; sites added more than about five months after the first patient contribute little, and late starters supplied under 10% of enrolment in 11 of 14 large trials (Li (Phesi) 2018; Haidich and Ioannidis 2003; Tufts CSDD 2013; Phesi 2023; D20). |
| Share of rescue sites that recruit nobody | 0.19 | Between 11% and 27% of added sites enrolled nobody; the midpoint is used (Li (Phesi) 2018; Tufts CSDD 2013; D20). |
| Months from opening to full rate: none in the first month, full by the third | 3 | A new site’s first month was assumed empty in the STAR pilot, good independent sites screened a first patient a median 20 days after activation, and 61% of UK studies recruited within 30 days of opening (Bertram 2019; CRIO 2026; UK KPIs 2026; D20). |
| Months from deciding to add a site to its opening: United States, independent site | 4.4 | US independent sites activated in a median 4.4 months (Smith (WCG) 2024; D20). |
| Months from deciding to add a site to its opening: United States, academic or hospital site | 8.1 | US academic and hospital sites activated in a median 8.1 months (Smith (WCG) 2024; D20). |
| Months from deciding to add a site to its opening: United Kingdom | 4 | A median 122 days from application to first participant, 2025 cohort (UK KPIs 2026; D20). |
Early-warning settings (6)
| Number | Value | Source |
|---|---|---|
| Tailwind factor | 0 | One measured case: Poland’s recruiting sites rose 10% while Ukraine’s fell 48% (Phesi via Lab News 2022; D41). |
| Watch threshold | 30 | No published calibration exists; to be tuned by a backtest against Medidata’s monthly series that reports lead time against false alarms (Medidata Releases 2.0 and 9.02; D42). |
| Act threshold | 60 | No published calibration exists; to be tuned by the same backtest (Medidata Releases 2.0 and 9.02; D42). |
| Impact visible below | 80 | A convenient rule that the UK met in the first month of the pandemic, when new patients fell more than 20% below 2019 in March 2020 (Medidata Release 2.0; D42). |
| Lost sales per day of delay, low | 500,000 | The median across medicines (Smith, DiMasi and Getz 2024; D47). |
| Lost sales per day of delay, high | 800,000 | The Tufts white paper’s estimate (Smith, DiMasi and Getz, white paper 2024; D47). |
News categories (16)
| Number | Value | Source |
|---|---|---|
| Public health: half-life | 60 days | The pandemic’s hit to new patients per site halved in about two months (Medidata Release 9.0; D40). |
| Public health: proximity weights | 1, 0.9, 0.7, 0.5 | Distance barely weakens the signal: WHO’s global declarations came weeks before recruitment collapsed country by country (WHO 2020; Medidata Release 2.0; D41). |
| Conflict & security: half-life | 365 days | Ukraine’s recruiting sites were 48% down at seven months and 62% down at 13 months, with no recovery (Phesi via Lab News 2022 and 20232; D40). |
| Conflict & security: proximity weights | 1, 0.5, 0.2, 0 | The effect falls steeply with distance, and next door it can be a gain: Poland’s recruiting sites rose 10% (Clinical Research News 2022; Phesi via Lab News 2022; D41). |
| Natural disaster: half-life | 60 days | No study measured how quickly recruitment recovers after a disaster; 60 days is an epiClinical assumption. |
| Natural disaster: proximity weights | 1, 0.3, 0.1, 0 | The damage is local: hospitals near the epicentre were lost while those further away kept working (IFRC 2023; D41). |
| Health system capacity: half-life | 21 days | Strikes and cyberattacks fade in two to four weeks: hospital activity dipped on strike days and recovered after them (Wyatt et al. 2026; Borchert et al. 2025; D40). |
| Health system capacity: proximity weights | 1, 0.8, 0, 0 | A strike reaches the sites of the health system on strike, and no further; the weights are epiClinical assumptions. |
| Policy & funding: half-life | 365 days | Funding cuts and new laws act for a year or more, and a law counts from the day it takes effect, however old the news (D40, D43). |
| Policy & funding: proximity weights | 1, 0.8, 0, 0 | A national law or funder reaches that country’s sites; the weights are epiClinical assumptions. |
| Regulatory: half-life | 365 days | A regulator’s or court’s rule stays live from publication until it takes effect, then fades over a year or more (D40, D43). |
| Regulatory: proximity weights | 1, 0.9, 0, 0 | A national rule applies to every site in the country; the weights are epiClinical assumptions. |
| Trust & access: half-life | 365 days | Mistrust is a slow headwind: the effect of the Tuskegee study on Black men’s use of care lasted decades (Alsan and Wanamaker 2018; D43). |
| Trust & access: proximity weights | 1, 0.6, 0, 0 | The weights are epiClinical assumptions. |
| Population movement: half-life | 60 days | People who move need continuity of care, not a change to the forecast, so these events carry no score; the half-life is an epiClinical assumption. |
| Population movement: proximity weights | 1, 0.8, 0.4, 0 | The weights are epiClinical assumptions. |
The works, chapter by chapter
Each work is listed once, under the first chapter that cites it. 253 of the 768 are cited on this site and marked "Cited here".
Chapter 1 How often recruitment fails, and which statistics to trust
- Advarra (formerly Forte Research). Retention in clinical trials: keeping patients on protocols (infographic; data from Clinical Performance Partners and Phesi 1998-2012 and CISCRP surveys).
- Bennette CS, Ramsey SD, McDermott CL, et al. Predicting low accrual in the National Cancer Institute's Cooperative Group clinical trials. Journal of the National Cancer Institute. 2016.
- Bertram W, Moore A, Wylde V, Gooberman-Hill R. Optimising recruitment into trials using an internal pilot. Trials. 2019.
- Bogin V. Lasagna's law: a dish best served early. Contemporary Clinical Trials Communications. 2022.
- Briel M, Olu KK, von Elm E, et al. A systematic review of discontinued trials suggested that most reasons for recruitment failure were preventable. Journal of Clinical Epidemiology. 2016.
- Brøgger-Mikkelsen M, Ali Z, Zibert JR, Andersen AD, Thomsen SF. Online patient recruitment in clinical trials: systematic review and meta-analysis. Journal of Medical Internet Research. 2020.
- Brøgger-Mikkelsen M, Zibert JR, Andersen AD, et al. Changes in key recruitment performance metrics from 2008-2019 in industry-sponsored phase III clinical trials registered at ClinicalTrials.gov. PLoS ONE. 2022.
- Campbell MK, Snowdon C, Francis D, et al. Recruitment to randomised trials: strategies for trial enrolment and participation study. The STEPS study. Health Technology Assessment. 2007.
- Carlisle B, Kimmelman J, Ramsay T, MacKinnon N. Unsuccessful trial accrual and human subjects protections: an empirical analysis of recently closed trials. Clinical Trials. 2015.
- Chaudhari N, Ravi R, Gogtay NJ, Thatte UM. Recruitment and retention of the participants in clinical trials: challenges and solutions. Perspectives in Clinical Research. 2020.
- Cheng SK, Dietrich MS, Dilts DM. A sense of urgency: evaluating the link between clinical trial development time and the accrual performance of CTEP-sponsored studies. Clinical Cancer Research. 2010.
- Clinical Leader. Considerations for improving patient recruitment (white paper teaser).
- Clinical Trials Arena (GlobalData). Clinical trial delays: America's patient recruitment dilemma. 2012.
- Crocker JC, Ricci-Cabello I, Parker A, et al. Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis. BMJ. 2018.
- DataAlly. Clinical trial enrollment statistics (secondary aggregator blog). 2025.
- Desai M. Recruitment and retention of participants in clinical studies: critical issues and challenges (editorial). Perspectives in Clinical Research. 2020.
- Dombernowsky T, Haedersdal M, Lassen U, Thomsen SF. Criteria for site selection in industry-sponsored clinical trials: a survey among decision-makers in biopharmaceutical companies and clinical research organizations. Trials. 2019.
- Donovan JL, Rooshenas L, Jepson M, et al. Optimising recruitment and informed consent in randomised controlled trials: the development and implementation of the Quintet Recruitment Intervention (QRI). Trials. 2016.
- Fierce Biotech. New research from Tufts Center for the Study of Drug Development characterizes effectiveness of clinical trial enrollment (press release; page returned HTTP 403). 2013.
- Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemporary Clinical Trials Communications. 2018.
- Gehring M, Taylor RS, Mellody M, et al. Factors influencing clinical trial site selection in Europe: the Survey of Attitudes towards Trial sites in Europe (the SAT-EU Study). BMJ Open. 2013.
- Getz K. Enrollment performance: weighing the "facts". Applied Clinical Trials. 2012.
- Getz K. How much does a day of delay in a clinical trial really cost? Applied Clinical Trials. 2024.
- Getz KA, Campo RA. New benchmarks characterizing growth in protocol design complexity. Therapeutic Innovation and Regulatory Science. 2018.
- Getz KA, Stergiopoulos S, Short M, et al. The impact of protocol amendments on clinical trial performance and cost. Therapeutic Innovation and Regulatory Science. 2016.
- Getz KA, Wenger J, Campo RA, Seguine ES, Kaitin KI. Assessing the impact of protocol design changes on clinical trial performance. American Journal of Therapeutics. 2008.
- Gillies K, Kearney A, Keenan C, et al. Strategies to improve retention in randomised trials. Cochrane Database of Systematic Reviews. 2021.
- Goyal A, Schibler T, Alhanti B, et al. Assessment of North American clinical research site performance during the start-up of large cardiovascular clinical trials. JAMA Network Open. 2021.
- Healy P, Galvin S, Williamson PR, et al. Identifying trial recruitment uncertainties using a James Lind Alliance Priority Setting Partnership: the PRioRiTy study. Trials. 2018.
- HIT Consultant. If everyone claims to accelerate clinical trials, why are we still falling behind? (seen in search index only). 2026.
- Houghton C, Dowling M, Meskell P, et al. Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis. Cochrane Database of Systematic Reviews. 2020.
- Huang GD, Bull J, Johnston McKee K, et al. Clinical trials recruitment planning: a proposed framework from the Clinical Trials Transformation Initiative. Contemporary Clinical Trials. 2018.
- Hulstaert L, Twick I, Sarsour K, Verstraete H. Enhancing site selection strategies in clinical trial recruitment using real-world data modeling. PLoS One. 2024.
- Institute of Medicine. A National Cancer Clinical Trials System for the 21st Century: Reinvigorating the NCI Cooperative Group Program, summary chapter. 2010.
- IQVIA Institute. Global Trends in R&D 2025 (press release, 15 April 2025). 2025.
- IQVIA Institute. Global R&D Trends 2026 (summary page, 25 March 2026). 2026.
- Jacques RM, Ahmed R, Harper J, et al. Recruitment, consent and retention of participants in randomised controlled trials: a review of trials published in the NIHR Journals Library (1997-2020). BMJ Open. 2022.
- Johnson O. An evidence-based approach to conducting clinical trial feasibility assessments. Clinical Investigation. 2015.
- Kasenda B, von Elm E, You J, et al. Prevalence, characteristics, and publication of discontinued randomized trials. JAMA. 2014.
- Kearney A, Harman NL, Rosala-Hallas A, et al. Development of an online resource for recruitment research in clinical trials to organise and map current literature. Clinical Trials. 2018.
- Knottnerus JA, Tugwell P. Prevention of premature trial discontinuation: how to counter Lasagna's law. Journal of Clinical Epidemiology. 2016.
- Korn EL, Freidlin B, Mooney M, Abrams JS. Accrual experience of National Cancer Institute Cooperative Group phase III trials activated from 2000 to 2007. Journal of Clinical Oncology. 2010.
- Lab News. A fifth of cancer trial sites enrol only one patient. 2023.
- Lasagna L. Problems in publication of clinical trial methodology. Clinical Pharmacology and Therapeutics. 1979.
- Li G (Phesi). Phesi report: assessing single-patient investigator sites in cancer clinical trials. Applied Clinical Trials. 2023.
- McDonald AM, Knight RC, Campbell MK, et al. What influences recruitment to randomised controlled trials? A review of trials funded by two UK funding agencies. Trials. 2006.
- McDonald K, Saini KS, Lu M, et al. Quantifying the impact of the COVID-19 pandemic on clinical trial enrollment rates over time in 37 countries. Research Square preprint, 23 November 2022; version of record Trials 2023, DOI 10.1186/s13063-023-07277-1, record unreachable at time of writing. 2022.
- Medidata Solutions. Non-enrolling and high-enrolling site data. Applied Clinical Trials. 2012.
- MESM (press release on Pharmaceutical Technology, GlobalData). Clinical research delays.
- MRC Network of Hubs for Trials Methodology Research. SWAT and SWAR resources page.
- Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004.
- ORRCA. Online Resource for Research in Clinical triAls, viewed October 2026. 2026.
- Phesi. News listing, viewed October 2026. 2026.
- Regulatory Focus (RAPS). Study: clinical trial site activation, enrollment difficulties slow product approvals. 2013.
- Rooshenas L, Scott LJ, Blazeby JM, et al. The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology. 2019.
- Sateren WB, Trimble EL, Abrams J, et al. How sociodemographics, presence of oncology specialists, and hospital cancer programs affect accrual to cancer treatment trials. Journal of Clinical Oncology. 2002.
- Schroen AT, Petroni GR, Wang H, et al. Preliminary evaluation of factors associated with premature trial closure and feasibility of accrual benchmarks in phase III oncology trials. Clinical Trials. 2010.
- Schroen AT, Petroni GR, Wang H, et al. Challenges to accrual predictions to phase III cancer clinical trials: a survey of study chairs and lead statisticians of 248 NCI-sponsored trials. Clinical Trials. 2011.
- Schroen AT, Petroni GR, Wang H, et al. Achieving sufficient accrual to address the primary endpoint in phase III clinical trials from US Cooperative Oncology Groups. Clinical Cancer Research. 2012.
- Smith B, Martin L, Martin S, et al. What drives site performance in clinical trials? Nature Reviews Drug Discovery. 2018.
- Smith Z, DiMasi J, Getz K. Quantifying the value of a day of delay in drug development (white paper). Tufts CSDD. 2024.
- Smith ZP, DiMasi JA, Getz KA. New estimates on the cost of a delay day in drug development. Therapeutic Innovation and Regulatory Science. 2024.
- Stensland KD, McBride RB, Latif A, et al. Adult cancer clinical trials that fail to complete: an epidemic? Journal of the National Cancer Institute. 2014.
- Sully BGO, Julious SA, Nicholl J. A reinvestigation of recruitment to randomised, controlled, multicenter trials: a review of trials funded by two UK funding agencies. Trials. 2013.
- Tejeda HA, Green SB, Trimble EL, et al. Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. Journal of the National Cancer Institute. 1996.
- Treweek S, Bevan S, Bower P, et al. Trial Forge Guidance 1: what is a Study Within A Trial (SWAT)? Trials. 2018.
- Treweek S, Pitkethly M, Cook J, et al. Strategies to improve recruitment to randomised trials. Cochrane Database of Systematic Reviews. 2018.
- Trial Forge. Home page and SWAT catalogue, viewed October 2026. 2026.
- Unger JM, Blanke CD, LeBlanc M, Hershman DL. Association of the coronavirus disease 2019 (COVID-19) outbreak with enrollment in cancer clinical trials. JAMA Network Open. 2020.
- Unger JM, Cook E, Tai E, Bleyer A. The role of clinical trial participation in cancer research: barriers, evidence, and strategies. ASCO Educational Book. 2016.
- Unger JM, Hershman DL, Till C, et al. "When offered to participate": a systematic review and meta-analysis of patient agreement to participate in cancer clinical trials. Journal of the National Cancer Institute. 2021.
- Unger JM, Shulman LN, Facktor MA, et al. National estimates of the participation of patients with cancer in clinical research studies based on Commission on Cancer accreditation data. Journal of Clinical Oncology, as reported by The ASCO Post. 2024.
- Unger JM, Vaidya R, Hershman DL, Minasian LM, Fleury ME. Systematic review and meta-analysis of the magnitude of structural, clinical, and physician and patient barriers to cancer clinical trial participation. Journal of the National Cancer Institute. 2019.
- van den Hoek TC, Ferrari MD. Reverse Lasagna's law: the ethics and undesirable consequences of overbooking patients for trials. European Journal of Neurology. 2023.
- van der Wouden JC, Blankenstein AH, Huibers MJH, et al. Survey among 78 studies showed that Lasagna's law holds in Dutch primary care research. Journal of Clinical Epidemiology. 2007.
- Walters SJ, Bonacho dos Anjos Henriques-Cadby I, Bortolami O, et al. Recruitment and retention of participants in randomised controlled trials: a review of trials funded and published by the UK Health Technology Assessment Programme. BMJ Open. 2017.
- WCG. By the Numbers: six challenges to enrollment, one customized solution (cites Tufts CSDD Impact Report March/April 2017 and WCG proprietary data). About. 2017.
- Whitham D, Turzanski J, Bradshaw L, et al. Development of a standardised set of metrics for monitoring site performance in multicentre randomised trials: a Delphi study. Trials. 2018.
Chapter 2 Protocol and study design
- Angus DC, Berry S, Lewis RJ, et al. The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study: Rationale and Design. Ann Am Thorac Soc 17(7):879-891. 2020.
- Applied Clinical Trials. Heavy burden: protocol design (May 2010; trade press, secondary). 2010.
- Beardsley E, Jefford M, Mileshkin L. Longer consent forms for clinical trials compromise patient understanding: so why are they lengthening? J Clin Oncol 25(9):e13-e14 (letter; figures not retrieved). 2007.
- Bell SA, Tudur Smith C. A comparison of interventional clinical trials in rare versus non-rare diseases: an analysis of ClinicalTrials.gov. Orphanet J Rare Dis 9:170. 2014.
- Botto E, Smith Z, Getz K. New Benchmarks on Protocol Amendment Experience in Oncology Clinical Trials. Ther Innov Regul Sci 58(4):645-654. 2024.
- Brown T, Jones T, Gove K, et al. Randomised controlled trials in severe asthma: selection by phenotype or stereotype. Eur Respir J 52(6):1801444. 2018.
- Cameron D, Willoughby C, Messer D, Lux M, Aitken M, Getz K. Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. Clin Ther 42(8):e150-e159. 2020.
- Clinical Trials Transformation Initiative. Recruitment (recommendations landing page; key materials uploaded 2021). 2021.
- Denicoff AM, Ivy SP, Tamashiro TT, et al. Implementing Modernized Eligibility Criteria in US National Cancer Institute Clinical Trials. J Natl Cancer Inst 114(11):1437-1440. 2022.
- DiMasi JA, et al. Assessing the Financial Value of Decentralized Clinical Trials. Ther Innov Regul Sci 57(2):209-219. 2023.
- Dirks A, Botto E, Smith Z, Getz K. Trends in the Burden for Patients Participating in Industry-Funded Clinical Trials. Ther Innov Regul Sci 59(5):893-900. 2025.
- Donovan JL, Jepson M, Rooshenas L, et al. Development of a new adapted QuinteT Recruitment Intervention (QRI-Two). Trials 23:258. 2022.
- Dumville JC, Hahn S, Miles JNV, Torgerson DJ. The use of unequal randomisation ratios in clinical trials: a review. Contemp Clin Trials 27(1):1-12. 2006.
- European Medicines Agency. ICH E8(R1) General Considerations for Clinical Studies: EMA adoption page (first published 14 October 2021; effective 14 April 2022). 2021.
- Flaherty KT, Gray RJ, Chen AP, et al. Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: NCI-MATCH. J Clin Oncol 38(33):3883-3894. 2020.
- Florez M, Smith Z, Olah Z, Martin M, Getz K. Quantifying Site Burden to Optimize Protocol Performance. Ther Innov Regul Sci 58(2):347-356. 2024.
- Getz K, Smith Z, Botto E, Murphy E, Dauchy A. New Benchmarks on Protocol Amendment Practices, Trends and their Impact on Clinical Trial Performance. Ther Innov Regul Sci 58(3):539-548. 2024.
- Getz K, Smith Z, Kravet M. Protocol Design and Performance Benchmarks by Phase and by Oncology and Rare Disease Subgroups. Ther Innov Regul Sci 57(1):49-56. 2023.
- Getz KA. Improving Protocol Design Feasibility to Drive Drug Development Economics and Performance. Int J Environ Res Public Health 11(5):5069. 2014.
- Harris MS, Wichary J, Zadnik M, Reinisch W. Competition for Clinical Trials in Inflammatory Bowel Diseases. Gastroenterology 157(6):1457-1461.e2 (editorial; paywalled, figures not retrieved). 2019.
- Harvey RD, Bruinooge SS, Chen L, et al. Impact of Broadening Trial Eligibility Criteria for Patients with Advanced Non-Small Cell Lung Cancer: Real-World Analysis of Select ASCO-Friends Recommendations. Clin Cancer Res 27(9):2430-2434 (conference version J Clin Oncol 37(suppl):LBA108, 2019). 2021.
- Harvey RD, et al. Modernizing Clinical Trial Eligibility Criteria: Recommendations of the ASCO-Friends of Cancer Research Washout Period and Concomitant Medication Work Group. Clin Cancer Res 27(9):2400-2407. 2021.
- Hoertel N and colleagues. Generalizability of pharmacologic and psychotherapy trial results for late-life unipolar depression. Aging Ment Health 25(2):367-377. 2021.
- Hoertel N and colleagues (first author not captured in the record retrieved). Generalizability of Clinical Trial Results for Adolescent Major Depressive Disorder. Pediatrics 140(6):e20161701. 2017.
- Hoertel N, et al. Generalizability of clinical trial results for generalized anxiety disorder to community samples. Depress Anxiety 29(7):614-620. 2012.
- Hoertel N, et al. Generalizability of clinical trial results for bipolar disorder to community samples: findings from NESARC. J Clin Psychiatry 74(3):265-270. 2013.
- Jenkins V, Fallowfield L. Reasons for accepting or declining to participate in randomized clinical trials for cancer therapy. Br J Cancer 82(11):1783-1788. 2000.
- Jenkins V, Farewell V, Farewell D, et al. Drivers and barriers to patient participation in RCTs. Br J Cancer 108(7):1402-1407. 2013.
- Jones WS, Mulder H, Wruck LM, et al. Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease (ADAPTABLE). N Engl J Med. 2021.
- Kim ES, Bruinooge SS, Roberts S, et al. Broadening Eligibility Criteria to Make Clinical Trials More Representative: ASCO and Friends of Cancer Research Joint Research Statement. J Clin Oncol 35(33):3737-3744. 2017.
- Kim ES, Uldrick TS, Schenkel C, et al. Continuing to Broaden Eligibility Criteria to Make Clinical Trials More Representative and Inclusive: ASCO-Friends of Cancer Research Joint Research Statement. Clin Cancer Res 27(9):2394-2399. 2021.
- Lee DH, et al. Treatment patterns across lines of therapy for advanced NSCLC by biomarker group (Flatiron Health). Cancer Med. 2026.
- Liu R, Rizzo S, Whipple S, et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592(7855):629-633. 2021.
- Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J 146(2):250-257. 2003.
- Mills EJ, Seely D, Rachlis B, et al. Barriers to participation in clinical trials of cancer: a meta-analysis and systematic review of patient-reported factors. Lancet Oncol 7(2):141-148. 2006.
- Nassif M, et al. Recruitment Strategies of a Decentralized Randomized Placebo Controlled Clinical Trial: The CHIEF-HF Trial. J Card Fail 29(6):863-869. 2023.
- Pablos-Méndez A, Barr RG, Shea S. Run-in periods in randomized trials: implications for the application of results in clinical practice. JAMA 279(3):222-225. 1998.
- Park JJH, Siden E, Zoratti MJ, et al. Systematic review of basket trials, umbrella trials, and platform trials: a landscape analysis of master protocols. Trials 20:572. 2019.
- Park JW, Liu MC, Yee D, et al. Adaptive Randomization of Neratinib in Early Breast Cancer. N Engl J Med 375(1):11-22. 2016.
- PharmaTimes. Protocol complexity is increasing trial burden, Tufts study says (21 January 2008; trade press, secondary). 2008.
- Pica N, Bourgeois F. Discontinuation and Nonpublication of Randomized Clinical Trials Conducted in Children. Pediatrics 138(3):e20160223. 2016.
- Ran T, et al. Treatment patterns in EGFR-mutated metastatic NSCLC (Integra Connect real-world cohort). Cureus. 2025.
- RECOVERY Collaborative Group (Horby P, et al.). Dexamethasone in Hospitalized Patients with Covid-19 (preliminary report). N Engl J Med, published online 17 July. 2020.
- Schoenfeld AJ, et al. Non-driver mutation metastatic NSCLC: treatment patterns and attrition (COTA, 2015 to 2022). Future Oncol. 2025.
- Sevigny J, et al. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial. Alzheimer Dis Assoc Disord (PMID 26885819). 2016.
- Sheffield KM, et al. KRAS G12C-mutant NSCLC after first-line therapy: real-world treatment patterns (US EHR and CGDB). Cancers 18(17):2869. 2026.
- Smith Z, Wilkinson M, Carney C, Grove N, Qutab B, Getz K. Enhancing the Measure of Participation Burden in Protocol Design to Incorporate Logistics, Lifestyle, and Demographic Characteristics. Ther Innov Regul Sci 55(6):1239-1249. 2021.
- Souza M, et al. Enrollment in Metabolic Dysfunction-Associated Steatohepatitis Clinical Trials: A Pooled Analysis of Screen Failure Rates. Am J Gastroenterol. 2025.
- Sperling RA, Donohue MC, Raman R, et al. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals. JAMA Neurol 77(6):735-745. 2020.
- Spertus JA, et al. The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. Nat Med 28(4):809-813. 2022.
- Steg PG, López-Sendón J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 167(1):68-73. 2007.
- Taylor KM, Margolese RG, Soskolne CL. Physicians' reasons for not entering eligible patients in a randomized clinical trial of surgery for breast cancer. N Engl J Med 310(21):1363-1367. 1984.
- Travers J, et al. External validity of randomised controlled trials in asthma: to whom do the results of the trials apply? Thorax 62(3):219-223. 2007.
- Travers J, et al. External validity of randomized controlled trials in COPD. Respir Med 101(6):1313-1320. 2007.
- Tufts Center for the Study of Drug Development. Rising protocol complexity is hindering performance while driving up cost of clinical trials (press release, 17 July 2018; 9,737 protocols, 178 companies). 2018.
- Unger JM, Hershman DL, Fleury ME, Vaidya R. Association of Patient Comorbid Conditions With Cancer Clinical Trial Participation. JAMA Oncol 5(3):326-333. 2019.
- US FDA. Cancer Clinical Trial Eligibility Criteria: Brain Metastases. Final guidance, July. 2020.
- US FDA. Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients. Final guidance, July. 2020.
- US FDA. Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections. Final guidance, July. 2020.
- US FDA. Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies. Final guidance, July. 2020.
- US FDA. Conducting Clinical Trials With Decentralized Elements. Final guidance, September. 2024.
- US FDA. Enhancing Participation in Clinical Trials: Eligibility Criteria, Enrollment Practices, and Trial Designs. Final guidance, December 2025 (earlier final version November 2020 titled Enhancing the Diversity of Clinical Trial Populations). 2025.
- US FDA. Cancer Clinical Trial Eligibility Criteria: Performance Status. Final guidance, July. 2026.
- US FDA. Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications. Final guidance, July. 2026.
- US FDA. Cancer Clinical Trial Eligibility Criteria: Laboratory Values. Final guidance, July. 2026.
- Uzzan M, Bouhnik Y, Abreu M, et al. Declining Enrolment and Other Challenges in IBD Clinical Trials: Causes and Potential Solutions. J Crohns Colitis 17(7):1066-1078. 2023.
- Vashisht P, Sayles H, Cannella AC, Mikuls TR, Michaud K. Generalizability of Patients With Rheumatoid Arthritis in Biologic Agent Clinical Trials. Arthritis Care Res 68(10):1478-1488. 2016.
- Waksman R, et al. High screen failure rate in patients with resistant hypertension: Findings from SYMPLICITY HTN-3. Am Heart J. 2017.
- Wang H, Yee D. I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. Curr Breast Cancer Rep 11(4):303-310. 2019.
- Welton AJ, Vickers MR, Cooper JA, Meade TW, Marteau TM. Is recruitment more difficult with a placebo arm in randomised controlled trials? A quasirandomised, interview based study. BMJ 318(7191):1114-1117. 1999.
- Wong SE, et al. Screen Failure Rates in Contemporary Randomized Clinical Phase II/III Therapeutic Trials in Genitourinary Malignancies. Clin Genitourin Cancer. 2017.
- Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 159(3):469-473. 2002.
Chapter 3 Sites, sponsors, and the machinery of start-up
- AACI Corporate Roundtable Trial Activation Task Force. Accelerating Clinical Trial Activation: a Collaborative Framework for Managing Pre-Activation Protocol Amendments. 2026.
- ACRP. Survey Identifies Factors in Reducing Clinical Research Coordinator Turnover (Buchanan and Claassen, Mayo Clinic Proceedings: Innovations, Quality and Outcomes). 2021.
- ACRP. Fixing Feasibility: Collaborative Approaches for Redefining and Improving Site Selection. 2024.
- ACRP. ACRP Publishes Results from First-Ever National Workforce Survey. 2025.
- ACRP and TEConomy Partners. Special Report: An Assessment of the Adequacy of the Clinical Research Workforce (summary page).
- Advarra. The State of Clinical Trial Activation at Sites (Study Activation Report Survey). 2020.
- Anisimov VV, Fedorov VV. Modelling, prediction and adaptive adjustment of recruitment in multicentre trials, Statistics in Medicine 26(27):4958-4975. 2007.
- Bechtel J (SCRS). The Results Are In: Survey Reveals Barriers and Opportunities In Site Sustainability, Clinical Leader. 2024.
- Bourne Partners. Incremental Insights into Clinical Trial Site Networks: Key Takeaways from the SCRS Global Site Solutions Summit (secondary report of the SCRS 2024 survey). 2024.
- Brosteanu O, et al. Risk-adapted monitoring is not inferior to extensive on-site monitoring: Results of the ADAMON cluster-randomised study, Clinical Trials 14(6):584-596. 2017.
- Bruhn H, Treweek S, et al. Estimating Site Performance (ESP): can trial managers predict recruitment success at trial sites? An exploratory study, Trials 20:192. 2019.
- Cheng SK, Dietrich MS, Dilts DM. Predicting accrual achievement: monitoring accrual milestones of NCI-CTEP-sponsored clinical trials, Clinical Cancer Research 17(7):1947-1955. 2011.
- Clinical Research News. The Scope of Things: Source Preparation Emerges as a Clinical Trial Startup Bottleneck. 2026.
- Clinical Trial Vanguard. Tufts CSDD: New Insights on the Clinical Trial Industry (Getz at SCOPE Summit). 2024.
- Clinitiative Health Research. Research Brief RB-025: Coordinator Turnover and Workforce Stability Across the Site Network (vendor). 2026.
- ClinOops (originally published by Power). When Competing Trials Start Eating Your Enrollment (vendor, anecdotal). 2026.
- Contemporary Clinical Trials Communications. Trial-level factors affecting accrual and completion of oncology clinical trials: a systematic review. 2021.
- Cornea. Recruitment Strategies and Obstacles During the Zoster Eye Disease Study (PMID 39625123). 2024.
- Corneli A, et al. One and done: Reasons principal investigators conduct only one FDA-regulated drug trial, Contemporary Clinical Trials Communications 6:31-38. 2017.
- CRIO. What it takes to start a study: site start-up benchmarks (SASI analysis). 2026.
- Department of Health and Social Care and NIHR. UK Clinical Research Delivery key performance indicators: data to July 2026. 2026.
- Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials, Journal of Clinical Oncology 24(28):4545-4552. 2006.
- Dirks A, Chambers J, Getz K (Tufts CSDD). The Site Landscape Is Evolving, But How? Tufts CSDD Shares New Findings, Clinical Leader. 2026.
- Esin Attorney Partnership. Legal alert on Turkey's Regulation on Clinical Trials of Pharmaceuticals. 2023.
- Florence Healthcare. 2024 State of Technology Enabled Clinical Trials: Insights, Trends and Predictions. 2024.
- GC Trials. Turkey coverage page (vendor claims).
- Gehring M, et al. Factors influencing clinical trial site selection in Europe: the SAT-EU Study, BMJ Open 3:e002957. 2013.
- Getz K. Predicting Successful Site Performance, Applied Clinical Trials. 2011.
- Getz K, Lamberti MJ, Chakravarthy R. New Benchmarks for Trial Initiation Activities, Applied Clinical Trials. 2016.
- Getz K, Smith Z, Peachey J, Li G. Leveraging Data Insights to Address the Perils of Linear Practices in Site Identification and Activation, Applied Clinical Trials. 2022.
- Haidich AB, Ioannidis JP. Late-starter sites in randomized controlled trials, Journal of Clinical Epidemiology 56(5):408-415. 2003.
- Hillery S, et al. Accelerating start-up cycles in investigator-initiated multicenter clinical trials, Journal of Clinical and Translational Science 9(1):e249. 2025.
- Hurtado-Chong A, Joeris A, Hess D, Blauth M. Improving site selection in clinical studies: a standardised, objective, multistep method and first experience results, BMJ Open 7:e014796. 2017.
- Hutchinson N, Klas K, Carlisle BG, Polak M, Kimmelman J, Waligora M. Competition for recruitment in SARS-CoV-2 trials in the United States: a longitudinal cohort analysis, BMC Research Notes 15:368. 2022.
- Ivsin P. The One-And-Done Investigator: A Clinical Trial Story, Clinical Leader. 2024.
- Labiotech. Cancer trials recruitment (report of the Phesi analysis). 2023.
- Lamberti MJ, Dirks A, Howie R, Getz K. An Examination of the Role of the Clinical Research Associate and Factors Impacting Performance and Experience, Applied Clinical Trials. 2022.
- Li G, Correa K, Peachey J, Legagneur V (Phesi). Enrollment Cycle Times Can and Should Be Optimized, Applied Clinical Trials. 2018.
- Lord O'Shaughnessy. Commercial clinical trials in the UK: the Lord O'Shaughnessy review, final report. 2023.
- Medical Research Agency (ABM), Poland. Model tripartite agreement of the Polish Clinical Trials Network now available. 2023.
- Ministry of Health and Family Welfare, India. New Drugs and Clinical Trials Rules, 2019 (G.S.R. 227(E)). 2019.
- Miseta E. Getz: Site Activations Hurt By Commodity Mentality, Clinical Leader. 2016.
- Miseta E. Why Is Study Start-Up Still So Inefficient? (Tufts CSDD 2017 start-up study), Clinical Leader. 2017.
- Mitchell EJ, Godolphin PJ, Meakin G, Sprange K. Do investigator meetings improve recruitment rates in clinical trials? A retrospective before-and-after study of data from nine multi-centre clinical trials, Trials. 2020.
- Nelson S (WCG). Avoid Enrollment Pitfalls: Find Your Best-fit Clinical Trial Sites. 2018.
- Ninh A, Vu L, Butler D. Beyond prediction: an evidenced-based framework for assessing site selection decisions, Therapeutic Innovation and Regulatory Science. 2026.
- Parrish G, Minns LA. CRA Turnover Within Contract Research Organizations Post-COVID-19: A Cross-Sectional Study, Clinical Researcher 39(1). 2025.
- PharmaTimes. NIHR data reveals commercial study set up times reduce by a third. 2023.
- PharmaVoice. Too much of a good thing? A flood of data is slowing clinical trials (Tufts CSDD data study). 2025.
- Preston NJ, et al. Strategies designed to help healthcare professionals to recruit participants to research studies, Cochrane Database of Systematic Reviews 2:MR000036. 2016.
- Science 37. Science 37 and Tufts CSDD Publish Landmark Study on Direct-to-Patient Clinical Trial Site Performance (press release). 2026.
- Scout Clinical. 2024 Site Landscape Survey and How Scout Lifts Lingering Site Burden (secondary report of the SCRS 2024 survey). 2025.
- Shelford Group. Clinical trial setup performance and research activity across the Shelford Group (research dashboard; snippet only, not verified). 2026.
- Silverman E. What Patients? The Trouble With Trial Enrollment, Pharmalot (PDF copy). 2013.
- Smith S (WCG). Accelerating Clinical Trial Activation, Applied Clinical Trials. 2024.
- Smith V, Clarke M, Begley C, Devane D. SWAT-1: the effectiveness of a 'site visit' intervention on recruitment rates in a multi-centre randomised trial, Trials. 2015.
- Smith Z, Getz K, Weinstein D, Jones L, McKee K, Van Horn T. Evaluating the Impact of a Direct-to-Patient Clinical Trial Site on Performance, Access, and Patient Representation, Applied Clinical Trials. 2026.
- Snyder D, Freel S, Stroo M. Navigating Workforce Stability in Clinical Research, ACRP. 2025.
- Society for Clinical Research Sites. Sites Speak Out on Clinical Trial Technology Overload: An SCRS Survey (377 respondents). 2020.
- Society for Clinical Research Sites. Workforce Challenges at Clinical Research Sites. 2023.
- Society for Clinical Research Sites. The 2023 Site Landscape Survey white paper. 2024.
- Society for Clinical Research Sites. The Site Landscape: Benchmark Your Site, Part 1 (2025 SCRS European Site Landscape, European Site Solutions Summit slides). 2025.
- Society for Clinical Research Sites. White papers and guides listing page (links to the 2024 Site Landscape Survey White Paper and the 2025 SCRS Landscape Survey Report). 2025.
- Society for Clinical Research Sites. Payments Initiative.
- Society for Clinical Research Sites (survey distributed via Acurian). Meeting Clinical Trial Site Needs with Patient Recruitment Agency Services (315 responses). 2017.
- Society for Clinical Research Sites and Greenphire. Site Payments and Patient Reimbursements: A Global Perspective. 2017.
- Stroo M, Reyes C, Deeter C, Freel SA, Gaudaur H, Sloane R, Snyder DC. Trends in turnover and turbulence at a large academic medical center before and during COVID-19, Journal of Clinical and Translational Science 9(1):e134. 2025.
- Tang J, et al. Comprehensive analysis of the clinical immuno-oncology landscape, Annals of Oncology 29(1):84-91. 2018.
- Trials. Assessing site performance in the Altair study, a multinational clinical trial (PMID 25872747). 2015.
- Tufts Center for the Study of Drug Development. New Research from Tufts CSDD Characterizes Effectiveness and Variability of Patient Recruitment and Retention Practices (press release, BioSpace copy). 2013.
- Tufts CSDD Impact Report 24(2). Cost variation and mis-estimation characterize clinical trial budgets. 2022.
- van den Brink MJ, Hummel M, Lemstra M, Berger MY, Dekker JH, Blanker MH. Factors affecting patient recruitment to trials: qualitative research in general practice, BJGP Open 4(3). 2020.
- Wardyński and Partners. Legal framework for conducting clinical trials in Poland. 2023.
- WCG. 2024 Clinical Research Site Challenges Report. 2024.
- WCG. 2025 Site Challenges Report (611 sites). 2025.
- Whittaker R, Evans R, Santos S (PPD, Thermo Fisher Scientific). Optimizing Site Activation to Accelerate Clinical Trials, Clinical Leader white paper (vendor; body behind login).
- Xtalks. Tufts Report and Removing the Blinders in Site Selection (webinar with K. Getz and goBalto). 2016.
- Yang E, et al. Quantifying and visualizing site performance in clinical trials, Contemporary Clinical Trials Communications 9:108-114. 2018.
- Yu M, Zhong S, Xing Y, Wang L (AbbVie). Enrollment Forecast for Clinical Trials at the Planning Phase with Study-Level Historical Data, arXiv:2303.08065. 2023.
- Zahren C, Harvey S, Weekes L, Bradshaw C, Butala R, Andrews J, O'Callaghan S. Clinical trials site recruitment optimisation: Guidance from Clinical Trials: Impact and Quality, Clinical Trials 18(5):594-605. 2021.
Chapter 4 Patients: barriers and what moves them
- 42 U.S.C. 289a-2, Inclusion of women and minorities in clinical research (NIH Revitalization Act of 1993 section 492B; amended by Pub. L. 114-255, 2016). 1993.
- 42 U.S.C. 300gg-8, Coverage for individuals participating in approved clinical trials (ACA section 2709; added by Pub. L. 111-148 section 10103(c)). 2010.
- 42 U.S.C. 1396d(gg), Routine patient costs for items and services furnished in connection with participation in qualifying clinical trials (Clinical Treatment Act; added by Pub. L. 116-260 section 210(a)(2)). 2020.
- AgencyIQ. FDA begins restoring some documents following court order. 2025.
- Albrecht TL, Eggly SS, Gleason ME, et al. Influence of clinical communication on patients' decision making on participation in clinical trials. J Clin Oncol 26(16):2666–2673. 2008.
- Alsan M, Wanamaker M. Tuskegee and the health of black men. Q J Econ 133(1):407–455. 2018.
- Antidote. Vendor site, accessed 21 October 2026. 2026.
- Apostolaros M, Babaian D, Corneli A, et al. Legal, regulatory, and practical issues to consider when adopting decentralized clinical trials: recommendations from the Clinical Trials Transformation Initiative. Ther Innov Regul Sci 54(4):779–787. 2020.
- Applied Clinical Trials. Education and satisfaction disparities evident among European patients, public (CISCRP 2013 wave, n = 5,701). 2013.
- Applied Clinical Trials. Medicaid coverage of "routine costs" for clinical trials.
- ASCO Post. Implementation of CLINICAL TREATMENT Act advances, increasing access to cancer clinical trials. 2023.
- Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine (COVE). N Engl J Med 384:403–416. 2021.
- Bell S, Clarke R, Mounier-Jack S, Walker JL, Paterson P. Parents' and guardians' views on the acceptability of a future COVID-19 vaccine: a multi-methods study in England. Vaccine. 2020.
- Borno HT, Zhang L, Siegel A, Chang E, Ryan CJ. At what cost to clinical trial enrollment? A retrospective study of patient travel burden in cancer clinical trials. Oncologist 23(10):1242–1249. 2018.
- Bryant J, Powell J. Payment to healthcare professionals for patient recruitment to trials: a systematic review. BMJ 331(7529):1377–1378. 2005.
- Byrne LM, Cook SK, Kennedy N, et al. Opening doors to clinical trial participation among Hispanics: lessons learned from the Spanish translation of ResearchMatch. J Clin Transl Sci. 2020.
- Caldwell PH, Hamilton S, Tan A, Craig JC. Strategies for increasing recruitment to randomised controlled trials: systematic review. PLoS Med 7(11):e1000368. 2010.
- Cartmell KB, Bonilha HS, Simpson KN, Ford ME, Bryant DC, Alberg AJ. Patient barriers to cancer clinical trial participation and navigator activities to assist. Adv Cancer Res 146:139–166. 2020.
- Centers for Medicare and Medicaid Services. National Coverage Determination 310.1, Routine Costs in Clinical Trials (version 2, effective 9 July 2007; superseded 27 May 2024). 2007.
- Chansky MC, et al. Process and outcome evaluation of the NIH Community Engagement Alliance. Public Health Rep. 2026.
- Cheng AC, et al. ResearchMatch on FHIR: development and evaluation of a recruitment registry and EHR system interface for volunteer profile completion. J Clin Transl Sci. 2023.
- CISCRP. 2019 Perceptions and Insights Study: Deciding to Participate (report deck, n = 12,451). 2019.
- CISCRP. 2023 Perceptions and Insights Study: Deciding to Participate (report deck, n = 12,017). 2024.
- CISCRP. Results from CISCRP's 2023 Perceptions and Insights Study (web summary). 2024.
- Clinical Trials Arena. Judge orders FDA to reinstate clinical trial diversity webpages. 2025.
- Clinical Trials Transformation Initiative. CTTI Recommendations: Decentralized Clinical Trials. 2018.
- CNBC. Moderna slows coronavirus vaccine trial enrollment to ensure minority representation, CEO says (figures as reported; page not directly retrievable). 2020.
- Comis RL, Miller JD, Aldigé CR, Krebs L, Stoval E. Public attitudes toward participation in cancer clinical trials. J Clin Oncol 21(5):830–835. 2003.
- Coyle J, et al. Learning from remote decentralised clinical trial experiences: a qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders. Br J Clin Pharmacol. 2022.
- Daniel N, et al. Enablers and barriers to participation in vaccine trials: a narrative synthesis. Vaccine. 2026.
- Davis S, et al. Ethics committees and the changed clinical research environment in India in 2016: a perspective. Perspect Clin Res. 2017.
- Day S, et al. Barriers and facilitators of participation in syphilis vaccine trials: a qualitative analysis to inform trial design and community engagement in the United States. Sex Reprod Health Matters. 2024.
- Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico (PREVENT-19). N Engl J Med 386(6):531–543. 2022.
- Edwards PJ, Roberts I, Clarke MJ, et al. Methods to increase response to postal and electronic questionnaires. Cochrane Database Syst Rev 3:MR000008. 2009.
- Embi PJ, Jain A, Clark J, Bizjack S, Hornung R, Harris CM. Effect of a clinical trial alert system on physician participation in trial recruitment. Arch Intern Med 165(19):2272–2277. 2005.
- Embi PJ, Leonard AC. Evaluating alert fatigue over time to EHR-based clinical trial alerts: findings from a randomized controlled study. J Am Med Inform Assoc. 2012.
- Enama ME, Hu Z, Gordon I, Costner P, Ledgerwood JE, Grady C. Randomization to standard and concise informed consent forms: development of evidence-based consent practices. Contemp Clin Trials 33(5):895–902. 2012.
- Fioravanti P, et al. Analysis of registered clinical trials in Italy regarding dermatology (2003–2022). Ital J Dermatol Venereol. 2024.
- Fletcher I, et al. A qualitative study to explore how to increase participation of South Asian women in gestational diabetes clinical trials. Research Square preprint. 2026.
- Ford JG, Howerton MW, Lai GY, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 112(2):228–242. 2008.
- Fouad MN, Acemgil A, Bae S, et al. Patient navigation as a model to increase participation of African Americans in cancer clinical trials. J Oncol Pract 12(6):556–563. 2016.
- Frampton GK, Shepherd J, Pickett K, Griffiths G, Wyatt JC. Digital tools for the recruitment and retention of participants in randomised controlled trials: a systematic map. Trials 21:478. 2020.
- Galsky MD, Stensland KD, McBride RB, et al. Geographic accessibility to clinical trials for advanced cancer in the United States. JAMA Intern Med 175(2):293–295. 2015.
- Goel K, et al. Community health workers' willingness to participate in COVID-19 vaccine trials and intention to vaccinate: a cross-sectional survey in India. Clin Epidemiol Glob Health. 2022.
- Goodson N, et al. Opportunities and counterintuitive challenges for decentralized clinical trials to broaden participant inclusion. NPJ Digit Med. 2022.
- Gota V, et al. Quality of informed consent in cancer clinical trials in India: a cross-sectional survey. Natl Med J India. 2018.
- Halpern SD, Chowdhury M, Bayes B, et al. Effectiveness and ethics of incentives for research participation: 2 randomized clinical trials. JAMA Intern Med 181(11):1479–1488. 2021.
- Hamel LM, Penner LA, Albrecht TL, Heath E, Gwede CK, Eggly S. Barriers to clinical trial enrollment in racial and ethnic minority patients with cancer. Cancer Control 23(4):327–337. 2016.
- Harris PA, Scott KW, Lebo L, Hassan N, Lightner C, Pulley J. ResearchMatch: a national registry to recruit volunteers for clinical research. Acad Med. 2012.
- Healthcare Innovation. New law requires Medicaid coverage of clinical trial participation. 2021.
- Heller C, Balls-Berry JE, Nery JD, et al. Strategies addressing barriers to clinical trial enrollment of underrepresented populations: a systematic review. Contemp Clin Trials 39(2):169–182. 2014.
- Hewston P, et al. Virtual GERAS DANcing for Cognition Exercise (DANCE) for older adults at home: a randomized feasibility trial. Pilot Feasibility Stud. 2026.
- Hilal O, et al. Connecting patients with clinical trials using patient navigation: a scoping review. Curr Oncol. 2026.
- Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 341(27):2061–. 1999.
- Jin X, Chandramouli C, Allocco B, Gong E, Lam CSP, Yan LL. Women's participation in cardiovascular clinical trials from 2010 to 2017. Circulation 141(7):540–548. 2020.
- Journal for Clinical Studies. Clinical trial in Central and Eastern Europe (industry). 2017.
- Khubchandani J, et al. COVID-19 vaccination hesitancy in the United States: a rapid national assessment. J Community Health. 2021.
- Kimmick GG, Peterson BL, Kornblith AB, et al. Improving accrual of older persons to cancer treatment trials: a randomized trial comparing an educational intervention with standard information: CALGB 360001. J Clin Oncol 23(10):2201–2207. 2005.
- King TL, et al. Malaysian patient perspectives on clinical trial participation: willingness, knowledge, perceptions, confidence, and religious barriers. Research Square preprint (later Sci Rep 2025). 2023.
- Knapp P, Bower P, Lidster A, et al. Why do patients take part in research? An updated overview of systematic reviews of psychosocial barriers and facilitators. Trials 26:174 (original: Sheridan R, et al. Trials 21:259, 2020). 2025.
- Kripalani S, et al. Disparities in research participation by level of health literacy. Mayo Clin Proc. 2021.
- Kubilay Tolunay P, Erol C, Kahraman S, et al. Understanding of clinical trials among patients with cancer and their relatives. JAMA Netw Open 8(1):e2457020. 2025.
- Lawrie K, et al. An exploration of the intersection of clinical trials and health literacy: a scoping review. J Health Care Poor Underserved. 2026.
- Loree JM, Anand S, Dasari A, et al. Disparity of race reporting and representation in clinical trials leading to cancer drug approvals from 2008 to 2018. JAMA Oncol 5(10):e191870 (read through the ASCO Post summary). 2019.
- Ludmir EB, Mainwaring W, Lin TA, et al. Factors associated with age disparities among cancer clinical trial participants. JAMA Oncol 5(12):1769–1773. 2019.
- Ma JE, et al. Provider interaction with an electronic health record notification to identify eligible patients for a cluster randomized trial of advance care planning in primary care: secondary analysis. J Med Internet Res. 2023.
- Makhnoon S, et al. Implementation of a patient navigation program to support representative participation in cancer clinical trials. Cancer Med. 2025.
- Marmara Medical Journal. Patients' motivation about clinical trials: a local perspective from Turkey (survey of 504 patients, Istanbul, 2008). 2011.
- Marquis-Gravel G, et al. Rationale and design of the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) trial. JAMA Cardiol 5(5):598–607. 2020.
- Mendiratta J, et al. Representation from India in multinational, interventional, phase 2 or 3 trials registered in Clinical Trials Registry-India: a cross-sectional study. PLoS One. 2023.
- Mensah GA, et al. Community Engagement Alliance (CEAL): a National Institutes of Health program to advance health equity. Am J Public Health 114(S1):S12–S17. 2024.
- Moseson H, et al. Comparison of study samples recruited with virtual versus traditional recruitment methods. Contemp Clin Trials Commun. 2020.
- Muthukumar AV, Morrell W, Bierer BE. Evaluating the frequency of English language requirements in clinical trial eligibility criteria: a systematic analysis using ClinicalTrials.gov. PLoS Med 18(9):e1003758. 2021.
- Nair A. Clinical research: regulatory uncertainty hits drug trials in India. Pharmaceutical Journal. 2015.
- NBC News (Reuters). Moderna vaccine trial contractors fail to enroll enough people of color, prompting slowdown. 2020.
- NIHR Be Part of Research. Over half a million people sign up to Be Part of Research. 2024.
- Nipp RD, Lee H, Powell E, et al. Financial burden of cancer clinical trial participation and the impact of a Cancer Care Equity Program. Oncologist 21(4):467–474. 2016.
- Nishimura A, Carey J, Erwin PJ, Tilburt JC, Murad MH, McCormick JB. Improving understanding in the research informed consent process: a systematic review of 54 interventions tested in randomized control trials. BMC Med Ethics 14:28. 2013.
- Nkoy FL, et al. Enhancing an existing clinical information system to improve study recruitment and census gathering efficiency. AMIA Annu Symp Proc. 2009.
- Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation (Apple Heart Study). N Engl J Med 381(20):1909–. 2019.
- Pew Research Center. Internet/Broadband Fact Sheet (NPORS 2026). 2026.
- PharmaTimes. Poland's cup runs over with clinical trials (industry commentary).
- Pillai GS, et al. Knowledge and perception of health-care professionals on clinical trials in India: a pan-Indian cross-sectional survey. Indian J Ophthalmol. 2023.
- Pillai GS, et al. Knowledge and awareness of clinical trials among trial participants in India: a multicentric questionnaire-based cross-sectional study. Indian J Ophthalmol. 2024.
- Porter G. Regulating clinical trials in India: the economics of ethics. Dev World Bioeth. 2018.
- Raftery J, Bryant J, Powell J, Kerr C, Hawker S. Payment to healthcare professionals for patient recruitment to trials: systematic review and qualitative study. Health Technol Assess 12(10). 2008.
- Ranjan R, et al. Factors influencing participation of healthy volunteers in clinical trials: findings from a cross-sectional study in Delhi, North India. Patient Prefer Adherence. 2019.
- Redacción Médica. España da un salto cualitativo en investigación clínica en una década (Farmaindustria). 2017.
- Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, Articles 28 and 31 (text on legislation.gov.uk). 2014.
- ResearchMatch. Site counters, accessed 21 October 2026. 2026.
- Roy Chaudhury R. Regulatory developments in the conduct of clinical trials in India. Glob Health Epidemiol Genom. 2016.
- Sariola S, et al. How civil society organisations changed the regulation of clinical trials in India. Sci Cult. 2019.
- Scharff DP, Mathews KJ, Jackson P, Hoffsuemmer J, Martin E, Edwards D. More than Tuskegee: understanding mistrust about research participation. J Health Care Poor Underserved 21(3):879–897. 2010.
- Sedrak MS, Freedman RA, Cohen HJ, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin 71(1):78–92. 2021.
- Sommer C, Zuccolin D, Arnera V, et al. Building clinical trials around patients: evaluation and comparison of decentralized and conventional site models in patients with low back pain. Contemp Clin Trials Commun 11:120–126. 2018.
- Steinberg JR, Turner BE, Weeks BT, et al. Analysis of female enrollment and participant sex by burden of disease in US clinical trials between 2000 and 2020. JAMA Netw Open 4(6):e2113749. 2021.
- Synnot A, Ryan R, Prictor M, Fetherstonhaugh D, Parker B. Audio-visual presentation of information for informed consent for participation in clinical trials. Cochrane Database Syst Rev 5:CD003717. 2014.
- Terraneo M, et al. Social capital and willingness to participate in COVID-19 vaccine trials: an Italian case-control study. BMC Public Health. 2022.
- The Pharma Letter. Spain above the European average in clinical trials in oncology (Farmaindustria data).
- Turner BE, Steinberg JR, Weeks BT, Rodriguez F, Cullen MR. Race/ethnicity reporting and representation in US clinical trials: a cohort study. Lancet Reg Health Am 11:100252. 2022.
- Turner L, et al. Faith, culture, and cancer: a qualitative study exploring Muslim women's perspectives on clinical trials in the United Kingdom. Health Expect. 2026.
- Unger JM, Coltman CA, Crowley JJ, et al. Impact of the year 2000 Medicare policy change on older patient enrollment to cancer clinical trials. J Clin Oncol 24(1):141–144. 2006.
- Unger JM, Hershman DL, Albain KS, et al. Patient income level and cancer clinical trial participation. J Clin Oncol 31(5):536–542. 2013.
- Unger JM, Moseley A, Symington B, Chavez-MacGregor M, Ramsey SD, Hershman DL. Geographic distribution and survival outcomes for rural patients with cancer treated in clinical trials. JAMA Netw Open 1(4):e181235. 2018.
- Unger JM, Xiao H, Vaidya R, Hershman DL. Medicaid expansion of the Patient Protection and Affordable Care Act and participation of patients with Medicaid in cancer clinical trials. JAMA Oncol 9(10):1371–1379. 2023.
- US Food and Drug Administration. Payment and Reimbursement to Research Subjects: Information Sheet. 2018.
- US Food and Drug Administration. Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: draft guidance page (court-order notice). 2024.
- US Food and Drug Administration, CDER. Drug Trials Snapshots Summary Report 2024. 2025.
- Van Spall HG, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 297(11):1233–1240. 2007.
- Vozpópuli. España consolida su liderazgo en ensayos clínicos pese a las trabas a la investigación (reporting IQVIA for EFPIA). 2024.
- Whitaker C, Stevelink S, Fear N. The use of Facebook in recruiting participants for health research purposes: a systematic review. J Med Internet Res 19(8):e290. 2017.
- Youssef E, et al. Understanding the barriers and enablers to participation in vaccine trials in a pregnant population from diverse ethnic background in an inner-city UK hospital. PLoS One. 2024.
- Zhang D, et al. Compromised informed consent due to functional health literacy challenges in Chinese hospitals. BMC Med Ethics. 2024.
Chapter 5 Countries and policy: the United States, the United Kingdom, and the European Union
- ABPI. Rescuing patient access to industry clinical trials in the UK. 2022.
- ABPI. Written evidence to the House of Commons Health and Social Care Committee. 2022/23. 2022.
- ABPI. Restoring the UK's global position in industry clinical trials (position paper). 16 November. 2023.
- ABPI. The road to recovery for UK industry clinical trials. December. 2024.
- ABPI. UK industry clinical trials: translating actions into impact. 2 December. 2025.
- ABPI. Decline in commercial clinical trial recruitment selling patients short, says ABPI. 2 December. 2025.
- ACSM Policy Corner. Federal government shutdown ends. November. 2025.
- ACSM Policy Corner. Court prevents NIH research award indirect cost cap policy, and another shutdown deadline approaches. 20 January. 2026.
- ACSM Policy Corner. February 2026 update. February. 2026.
- ACT EU. Accelerating clinical trials in the EU (homepage KPIs, data to end of June 2026). 2026.
- ACT EU and EMA. EU clinical trials during the 3-year CTR transition period (31 January 2022 to 30 January 2025). 2025.
- AIFA. Ethics Committees Coordination Centre (Centro di Coordinamento Nazionale dei Comitati Etici). 2025.
- AIFA. Clinical trials concerning medicinal products. 2025.
- American Council on Education. Trump administration does not seek to appeal to Supreme Court; indirect costs cap litigation concluded. 2026.
- Bennett Institute, University of Oxford. UK trials and Brexit. May. 2019.
- BfArM. Clinical trials (page). 2025.
- BioPharma Dive. HHS to cut 10,000 staff in major restructuring under RFK Jr. 27 March. 2025.
- British Journal of Cancer. Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework. 23 July. 2026.
- CCMO (Netherlands). English site (no statistics retrieved). 2025.
- CDC. ACIP membership roster. 2025.
- Cięszczyk et al. (PMC11270168). Knowledge and beliefs about clinical trials among adults in Poland. Clinics and Practice. 2024.
- Clinical Trials Arena. FDA winds down operations amid government shutdown. 2 October. 2025.
- Clinical Trials Arena. Reforms to UK clinical trial sector showing signs of success. 2026.
- Clinical Trials Arena. EU region sees increase in multinational trial initiation in Q1 2026. 21 May. 2026.
- CMS. NCD 310.1 Routine costs in clinical trials. 2007.
- Danish Medicines Agency. Clinical trials with medicinal products (updated 21 October 2026). 2026.
- Department of Health and Social Care. Full government response to the Lord O'Shaughnessy review into commercial clinical trials. 26 May 2023, updated 8 December. 2023.
- EFPIA. 35,000 more patients to get access to clinical trials if new EU targets are met. 24 February. 2026.
- EMA. Clinical trials: transition to new EU system, one year left. 31 January. 2024.
- EMA. Health technology assessment bodies. 2025.
- EMA. Clinical Trials Information System (CTIS) (page updated 2026, CTIS task force). 2026.
- European Commission. Reform of the EU pharmaceutical legislation (political agreement December 2025). 2025.
- European Commission. Health technology assessment: overview (Regulation (EU) 2021/2282). 2025.
- Farmaindustria. The Great Opportunity: Spain as a Global Hub for Pharmaceutical Innovation and Manufacturing. November. 2025.
- FDA. 21st Century Cures Act. 2025.
- Fierce Biotech. U.K. government-backed medical research shut down amid COVID-19. March. 2020.
- Fierce Biotech. NIH research grinds to a halt as government shuts down; and ASCO. Federal government shuts down after Congress fails to pass FY26 funding bill. October. 2025.
- Fierce Pharma. FDA staff cuts could disrupt drug reviews, putting agency's critical funding programs at risk. 2025.
- Forbes. Appeals court upholds ban against fed's plan to cap NIH indirect costs. 6 January. 2026.
- GOV.UK. Government drives forward its 150-day clinical trial target. 15 April. 2026.
- GOV.UK. Launch of clinical trial reforms. 27 April. 2026.
- GOV.UK. UK life sciences attracts £3bn investment, creating jobs and faster patient treatments (Life Sciences Sector Plan: one year on). 9 July. 2026.
- Grant Witness. NIH weekly report, 12 October 2026. 2026.
- Health Affairs Forefront. Unpacking the Supreme Court's decision over NIH funding. 2025.
- Health and Care Research Wales. Commercial study set up times reduced by a third, according to new data. 27 October. 2023.
- Health Policy Watch. NIH-funded human trials outside US get temporary funding reprieve. 2025.
- Holland & Knight. The NIH-proposed 15 percent indirect cost rate cap is out (for now). January. 2026.
- ICEX Invest in Spain. Spain, European leader in clinical drug research (AEMPS 2024 data). 2025.
- INFARMA and POLCRO. Industry clinical trials in Poland: global environmental scan and progress review through 2024 (local text copy). 2025.
- INFARMA, GCPpl, and POLCRO. Industry clinical trials in Poland: possibilities to increase number and scope of trials in Poland (LongTaal site-productivity and start-up benchmarks). 2021.
- Inside Health Policy. Diversity Action Plan guidance, other deleted documents restored. February. 2025.
- IQVIA for EFPIA and Vaccines Europe. Assessing the clinical trial ecosystem in Europe: final report. August to October. 2024.
- IQVIA Institute. Global R&D Trends 2026 (page). 25 March. 2026.
- Journal of Pharmaceutical Policy and Practice (PMC13270869). A mixed-methods evaluation of the quantitative and perceived impact of Brexit on UK oncology clinical trial initiation between 2011 and 2020. 2026.
- KFF. Health provisions in the 2025 federal budget reconciliation law. 2025.
- Medical Research Agency (ABM). English site. 2025.
- Medical Research Agency (PMC11699205). Medical Research Agency: 5 years of reshaping the clinical trials ecosystem in Poland. 2024/25. 2024.
- Medidata. COVID-19 and Clinical Trials: The Medidata Perspective, Release 9.0 (local text copy). 21 September. 2020.
- Medizinforschungsgesetz, Bundesgesetzblatt 2024 I Nr. 324 (23 October 2024, promulgated 29 October 2024). 2024.
- National Cancer Institute. Insurance coverage and clinical trials. 2025.
- National Health Executive. Commercial study set-up process over 100 days quicker thanks to National Contract Value Review. 2023.
- National Health Executive. NIHR investment launches UK-wide commercial research delivery network. 1 September. 2025.
- Nature Reviews Drug Discovery. Benchmarking recruitment rates for phase III trials (supplementary information). 2024.
- NHS England. Increasing research activity in the NHS (long read). 2025.
- NHS England, Accelerated Access Collaborative. National Contract Value Review. 2025.
- NIHR. NIHR issues final update on implementation of the Restart Framework. 2021.
- NIHR. Commercial study set up times reduced by a third. October. 2023.
- NIHR. New NIHR Research Delivery Network to deliver key government priority projects; and RDN, About us. 2024.
- pharmaphorum. ABPI says UK clinical trials sector 'improving'. 17 November. 2023.
- PLoS ONE (PMC8407556). Impacts of COVID-19 on clinical research in the UK: a multi-method qualitative case study. 2021.
- PMC11963400. Advocating for collaboration among key partners to promote diversity in clinical studies amid policy challenges in the USA. 2025.
- RAPS. EU regulators set targets to promote European clinical trials; and Pharmaceutical Technology. New targets for clinical trials in the European Union. 2026.
- RAPS Regulatory Focus. Former FDA officials, experts decry HHS staff cuts. 31 March. 2025.
- Real Decreto 1090/2015, de 4 de diciembre, por el que se regulan los ensayos clínicos con medicamentos (BOE 24 December 2015; in force 13 January 2016). 2015.
- Science. NIH funding policy deals new blow to HIV-related trial networks. 2025.
- SCOTUSblog. Supreme Court allows Trump administration to terminate $783 million in NIH grants linked to DEI initiatives. 21 August. 2025.
- STAT. NIH halts funding for new projects with foreign collaborators, citing national security concerns. 1 May. 2025.
- STAT. NIH funding survey shows sizable impact of foreign subaward ban. 27 March. 2026.
- The Medicines for Human Use (Clinical Trials) (Amendment) Regulations 2025, SI 2025/538, and explanatory memorandum. 2025.
- The Pharmaceutical Journal. Participation in commercial clinical trials falls for fourth year in a row, finds ABPI. 3 December. 2025.
- The White House. Restriction on entry of certain nonimmigrant workers (proclamation). 19 September. 2025.
- The White House. Delivering most-favored-nation prescription drug pricing to American patients (Executive Order 14297). 12 May. 2025.
- Ustawa z dnia 9 marca 2023 r. o badaniach klinicznych produktów leczniczych stosowanych u ludzi (Dz.U. 2023 poz. 605). 2023.
- Wellcome. Regulation of clinical trials: Brexit and beyond. 2019.
- Wikipedia. Tariffs in the second Trump administration (secondary; pharmaceuticals section; page carries a verification notice). 2025.
- Wikipedia. Biosecure Act (secondary; cites Congress.gov, Ropes & Gray, National Law Review January 2026). 2026.
- Wikipedia. Advisory Committee on Immunization Practices (secondary; cites ABC News, NYT, Reuters, CDC charter, AP). 2026.
- Wikipedia (French). Comité de protection des personnes (secondary; decree of 16 November 2016, 39 CPPs, 2022 reform). 2025.
- Wikipedia (German). Medizinforschungsgesetz (secondary; cites BGBl, BMG, and press sources). 2025.
- Wiley Rein. Update: federal judge blocks NIH cap on indirect rates for grants. 2025.
Chapter 6 Countries and policy: India, Turkey, and the rest of the world
- Al Jeraisy M, Turgonyi E, Misik V, Alaskar A. Bridging the clinical trial gap in Saudi Arabia: a multi-stakeholder conference-based consensus on strategic initiatives for global competitiveness and patient inclusion. Saudi Pharmaceutical Journal 34(4):44. 2026.
- AusBiotech and Biotech Dispatch. AusBiotech welcomes $13.6 million investment to strengthen clinical trials. 6 October. 2025.
- Axios. Pharma fallout from Iran war won't end with ceasefire. 9 April. 2026.
- Barnes M, Flaherty J, Caron M, Naqvee A, Bierer B. The evolving regulatory landscape for clinical trials in India. Food and Drug Law Journal 73:601. 2018.
- Beaney A. Israel prepared to keep clinical trials running during war. Clinical Trials Arena. 11 October. 2023.
- Beaney A. Iran-Israel conflict disrupts trial initiations. Clinical Trials Arena (GlobalData). 24 July. 2025.
- Beaney A. OCT West Coast 2025: China surpasses US for annual number of clinical trials. Clinical Trials Arena. 12 February. 2025.
- Beaney A. Data shows 6.7% of global clinical trials impacted by Middle East disruption. Clinical Trials Arena. 2 April. 2026.
- Bhatt A. International regulatory agencies: Indian clinical trials. Perspectives in Clinical Research 2(1):41. 2011.
- Bhide S, Patil S, Sohal A, et al. Investigator knowledge, awareness, and registrations of academic clinical trials with the Clinical Trial Registry of India. Perspectives in Clinical Research 14(4):187–193. 2023.
- Bhide SS, Tadavi FM, Maurya MR, Bhojne SK, Chandrakar P. Assessment of clinical trials registered at clinical trial registry of India over past decade: an audit. International Journal of Clinical Trials 3(4):238–243. 2016.
- Castañeda R. As Russia's clinical trials sector falls, Ukraine rebuilds. Clinical Trials Arena. 23 August. 2022.
- Castañeda R. Clinical trials in Russia: drug development pipeline at risk. Clinical Trials Arena. 7 March. 2022.
- Chawan VS, Gawand KV, Phatak AM. Impact of new regulations on clinical trials in India. International Journal of Clinical Trials 2(3):56–58. 2015.
- Clinical Trials Arena. UAE positions itself as a regional leader and a clinical trial hub.
- Clinical Trials Arena (GlobalData). Canada accounts for 3.8% share of global clinical trial activity in 2021. 1 April. 2022.
- Copelyn J. U.S. pulls funding for South African medical research. Spotlight and GroundUp, via AllAfrica. 9 May. 2025.
- Cullinan K. NIH cuts to South Africa will cause global loss of TB and HIV research capacity. Health Policy Watch. 15 May. 2025.
- Eglovitch JS. FDA turns attention to data integrity lapses at testing sites in new guidance. RAPS Regulatory Focus. 2 April. 2024.
- EMA Biostatistics Working Party. Points to consider on the impact of the war in Ukraine on methodological aspects of ongoing clinical trials (EMA/214249/2022). 13 April. 2022.
- European Business Association. Clinical trials in Ukraine 2022–2025: recovery dynamics and future outlook.
- European Medicines Agency. Synchron Research Services, Article 31 referral, Annex II: scientific conclusions. 2022.
- Farooq U. Lira crash slams Turkey's factories, farmers and retailers. Al Jazeera. 3 December. 2021.
- Federal Financial Relations. Commonwealth FFA for Encouraging More Clinical Trials to Australia, Queensland schedule. March. 2026.
- Fierce Biotech. FDA asks pharmas to repeat studies done at 2 Indian CROs due to data integrity issues. 2021.
- Garabetyan E. La investigación médica crece: Anmat ya aprobó más ensayos clínicos que durante todo 2025. Perfil. 15 October. 2026.
- Goldberg P, Tracey A. In a 14:1 vote, ODAC nixes a PD-1 drug developed in China; data not generalizable to U.S. population. The Cancer Letter. 11 February. 2022.
- Greenberg Traurig. BIOSECURE Act update: court enjoins WuXi AppTec's 1260H designation, but strategic and compliance clocks keep running. September. 2026.
- Gulf News. Argentina inflation seen at 126.4% in 2023, central bank poll shows. 2023.
- Gupta YK, Kumar BD. Clinical trials and evolving regulatory science in India. Indian Journal of Pharmacology 46(6):575–578. 2014.
- Hasanzadeh L. Navigating medicine pricing in Türkiye: the pharmaceutical euro exchange rate. Pharmaceutical Technology (GlobalData). 3 December. 2024.
- Holland & Knight. WuXi AppTec added to DOW's 1260H list: the BIOSECURE Act clock is running. June. 2026.
- Human L. World's largest research funder lifts ban on South Africa. GroundUp and Spotlight. 24 August. 2026.
- Ilancheran M. Measuring the impact of reforms on India's clinical trial environment. Clinical Leader. 12 October. 2017.
- Innovative Medicines Canada. Clinical trials in Canada 2023: research note. 2023.
- Innovative Medicines Canada. Clinical trials in Canada: research note, June 2025. 2025.
- Inter-Governmental Policy Reform Group. Newsletter. 20 May. 2026.
- IQVIA for AİFD. Benefits of a clinical research strategy for Turkey. September. 2020.
- IQVIA for the EFPIA Oncology Platform. The impact of the war in Ukraine on oncology patients. 2022–.
- IQVIA Laboratories. Delivering excellence in China.
- ITIF. Fact of the Week: China has surpassed the US in the number of drug clinical trials, with 1,100 more trials listed. 9 June. 2025.
- Jeong M. Korea ranks 5th in global share of pharmaceutical clinical trials. Korea Biomedical Review. 14 April. 2023.
- Kachkovska V, Anderson EE. Global pharmaceutical companies' obligations to restart clinical research in Ukraine. American Journal of Bioethics 25(4):32–35. 2025.
- Kawakita Y, Matsumoto K, Hirano M, et al. Reimagining early-phase clinical development in Japan: from regulatory obligation to global acceleration. Clinical and Translational Science 19(1):e70467. 2026.
- Kent C. Indian health ministry fast-tracks drug approvals with new clinical trial legislation. Clinical Trials Arena. 26 March. 2019.
- KoNECT. Start with Korea. May. 2025.
- Koyuncu O, Gursoz H, Alkan A, et al. Evaluation of the performance of the Turkish regulatory agency: recommendations for improved patients' access to medicines. Frontiers in Pharmacology 10:1557. 2020.
- Kwak S. Health ministry moves to tackle decline in Korea's clinical trials. Korea Biomedical Review. 10 July. 2025.
- Latham & Watkins. BIOSECURE Act becomes law limiting grants with biotechnology companies of concern. 31 December. 2025.
- Lawal S. African researchers are working to cure HIV, but US aid cuts are in the way. Al Jazeera. 1 May. 2025.
- MacPhail K. Q&A: How Trump's USAID freeze halted the effort to develop an effective HIV vaccine in Africa. STAT. 26 February. 2025.
- Martinez-Clark JG. Mexico is becoming Latin America's clinical trial powerhouse, while Colombia falls behind. bioaccess blog (vendor). 14 March. 2026.
- Mashaki Ceyhan E, Gürsöz H, Alkan A, et al. The Turkish Medicines and Medical Devices Agency: comparison of its registration process with Australia, Canada, Saudi Arabia, and Singapore. Frontiers in Pharmacology 9:9. 2018.
- MASSİAD. TİTCK Klinik Araştırma Etik Kurulları Hakkında (on TİTCK clinical-research ethics committees). 2 June. 2023.
- McKenzie H. CRO data integrity concerns have pharma companies scrambling to repeat bioequivalence studies. BioSpace. 29 September. 2021.
- Misik V. The impact of the Russia–Ukraine war on clinical trials. Clinical Leader. 7 September. 2022.
- Nathan A. War fractures emerging clinical trial infrastructure in the Middle East. The Scientist. 2026.
- NIAID ClinRegs. India country profile (updates to 2026). 2026.
- NIAID ClinRegs. China country profile (updates to 2026). 2026.
- NIAID ClinRegs. Brazil country profile (updates to 2026). 2026.
- NIAID ClinRegs. Mexico country profile (updates to 2026). 2026.
- NIAID ClinRegs. Canada country profile (updates to 2026). 2026.
- Ontario Leadership Table (Clinical Trials Ontario). Position paper. November. 2023.
- Outsourcing-Pharma. Finland, Brazil & Mexico top per site recruitment; visualisation (EMA 2005–2009 data). 30 November. 2010.
- Pacific Bridge Medical. Japan Phase 1 drug clinical trials no longer needed for global clinical trials. 29 September. 2023.
- Phesi. Almost half of Ukraine's clinical trials to find new therapies are still recruiting patients despite ongoing conflict. October. 2022.
- Phesi. New Phesi data shows 6.7% of global clinical trials impacted by Middle East disruption. 1 April. 2026.
- PMDA. PMDA Updates, July 2017 (ICH Assembly, Montreal, 27 May to 1 June 2017). 2017.
- Presidência da República. Lei nº 14.874, de 28 de maio de 2024 (Brazil's clinical research law). 2024.
- Ramírez Coronel M. Article in El Economista, 21 March 2021, republished by Salud y Fármacos. August. 2021.
- RAPS. Asia Regulatory Roundup: CFDA clampdown on clinical trial data. 17 November. 2015.
- Ravindranath AG, Benny A, Bhalla IS, Vaswani R, Saberwal G. Clinical trial registration in India: 12% of drug regulatory trials are not registered, as required by law. Health Research Policy and Systems 23:19. 2025.
- SAHPRA. Clinical trials.
- SAHPRA. Backlog.
- Science. NIH halts more collaborations with South Africa on HIV/AIDS trials (2025),. 2025.
- Shiga K, Shibata T, Miyata T. Evaluation of drug lag and drug loss in Japan: participation in global phase III oncology trials. International Journal of Clinical Oncology 30(6):1109–1117. 2025.
- Smooth Drug Development. Clinical trials in Turkey (vendor page, data to 2023). 2023.
- State Expert Center of the Ministry of Health of Ukraine. Key trends in the development of clinical trials of medicinal products in Ukraine in 2025. 17 February. 2026.
- Stockholm Center for Freedom (advocacy group). Survey shows purge of over 8,000 academics leads to 28 pct decrease in scientific research in Turkey.
- Tampal N (US FDA, Office of Generic Drugs). Impact assessment of FDA's data integrity notifications to sponsors. SBIA Generic Drugs Forum, 12–13 April. 2023.
- The Pathologist. Middle East conflict hits medical research. April. 2026.
- The Pharma Letter. Russia faced with decline of clinical trials of medicines (Vademecum and Kommersant data on 2022 permits). 2022.
- The Pharma Letter. Foreign CROs suspending participating in clinical trials in Russia (ACTO data, first half of 2023). 2023.
- The Pharma Letter. Iran war disrupts nearly 8,000 clinical trial sites. 2 April. 2026.
- The Tokyo Foundation. Addressing Japan's "drug loss, drug lag": an analysis and proposals for revamp. 6 September. 2024.
- Thomson Reuters. Overcoming clinical challenges in BRIC markets: a white paper. April 2014. No public URL recorded; cited via reference 1. 2014.
- TİTCK. 2021 Yılı İdare Faaliyet Raporu (activity report for 2021). 2022.
- TİTCK. 2022 Yılı İdare Faaliyet Raporu (activity report for 2022). 27 February. 2023.
- TİTCK. Klinik Araştırma Taraflarının Dikkatine (notice to clinical trial parties). 3 March. 2023.
- TİTCK. 2023 Yılı İdare Faaliyet Raporu (activity report for 2023). 4 March. 2024.
- TİTCK. 2024 Yılı İdare Faaliyet Raporu (activity report for 2024). 28 February. 2025.
- TİTCK. Klinik Araştırma İstatistikleri (2019–2025), presentation, linked from the TİTCK clinical-trials page. 2026.
- TİTCK. 2025 Yılı İdare Faaliyet Raporu (activity report for 2025). 27 February. 2026.
- TİTCK Klinik Araştırmalar Dairesi Başkanlığı. Deprem Afeti Nedeniyle Klinik Araştırmalarda Alınacak Tedbirler (measures to be taken in clinical trials due to the earthquake disaster), V1.0. 28 February. 2023.
- TÜBİTAK. 2023 Deprem Bölgesi Özel Çağrısı: TEKNOÇABA Açıldı (earthquake-zone special call, listing the 11 provinces). 2023.
- Turkish Minute (reporting BBC Turkish). Cancer drug shortage in Turkey raises treatment concerns. 30 April. 2026.
- UNHCR Türkiye. Provincial breakdown of Syrian refugees in Türkiye, as of 5 October 2023. 2023.
- University of Augsburg repository (authors not recorded). The impact of decree laws on the performance of Turkish academic family physicians: a repeated cross-sectional study.
- US FDA. Considerations for the conduct of clinical trials of medical products during major disruptions due to disasters and public health emergencies. Final guidance. September. 2023.
- Van Beusekom M. US cuts to HIV programs in sub-Saharan Africa pose global risk, experts say. CIDRAP. January. 2026.
- Weinreb G. Clinical trials in Israel decline sharply. Globes. 18 June. 2024.
- Xu L, Gao H, Kaitin KI, Shao L. Reforming China's drug regulatory system. Nature Reviews Drug Discovery 17:858–859. 2018.
- Zawya. Saudi's SFDA: 83% growth in clinical research for biotechnology products in 2025,. 2025.
Chapter 7 Shocks: pandemics, conflict, disasters, and the early-warning problem
- AACI Clinical Trials Office Staff Retention Task Force. 2022 to 2023 CTO Staff Retention Surveys. 2023.
- ACLED. About ACLED.
- Advarra. 2025 Workforce Development Survey Report. 2025.
- AEMPS. Medidas excepcionales aplicables a los ensayos clínicos para gestionar los problemas derivados de la emergencia por COVID-19 (16 March 2020, updated to 1 July 2020). 2020.
- Africa.com. Sudan's ongoing conflict has devastated key medical research infrastructure (reporting The Guardian, 8 May 2025). 2025.
- Aguero D, Allen. Weathering The Storm: Commentary on the Hurricane Helene IV Fluid Shortage. Journal of Pediatric Pharmacology and Therapeutics. 2024.
- Almagro P et al. Seasonality, ambient temperatures and hospitalizations for acute exacerbation of COPD: a population-based study in a metropolitan area. International Journal of COPD. 2015.
- American Hospital Association. Change Healthcare Cyberattack Underscores Urgent Need to Strengthen Cyber Preparedness. 2024.
- American Hospital Association. CrowdStrike Technology Outage Causing Global Disruption, Including Impacts on Hospitals (advisory, 19 July 2024). 2024.
- AONL, reporting MedPage Today on a JAMA Internal Medicine cross-sectional study (authors not retrieved). Thousands affected by cuts to NIH-funded clinical trials. 2025.
- Bakouny Z et al. Annals of Oncology 2022, reported in Healio, Cancer clinical trials recover from substantial disruption during COVID-19 pandemic. 2022.
- BioSpace. Vor Bio Looks for Exit in Challenging Funding Environment; Lays Off 95% of Staff. 2025.
- Bitdefender Hot for Security. COVID-19 Vaccine Trials Slowed Down by a Ransomware Attack. 2020.
- BleepingComputer. Synnovis notifies of data breach after 2024 ransomware attack. 2025.
- Borchert RJ et al. Impact of the junior doctors' industrial action on the efficiency of a radiology department. Clinical Radiology. 2025.
- Cancer Network. Hurricane-Hit Practice Offers Lessons in Disaster Planning.
- Cancer Research Institute and IQVIA. Cancer Research Institute and IQVIA Uncover the Impact of COVID-19 Pandemic on Global Oncology Clinical Trials. 2020.
- Chief Scientist Office (Scotland). CSO Statement on guidance to protect research during a second wave of COVID-19 activity. 2020.
- Clinical Leader. When Clinical Trials Don't Stop For War. 2026.
- Clinical Research News. In War-Torn Ukraine, Clinical Trials Trudge Along. 2022.
- Clinical Trials Arena. Israel prepared to keep clinical trials running if country goes to war. 2023.
- Clinical Trials Arena (GlobalData). Russia clinical trials fall as Ukraine rebuilds. 2022.
- CNN (Christensen J), republished by KEYT. Drug shortages' effects on cancer research may be felt for years to come. 2023.
- Cyprus Mail. Junior doctors in England plan more strikes in fight for better pay. 2023.
- De Guzman RB et al. Lung cancer in Asia: the impact of climate change. EClinicalMedicine. 2024.
- Detoc M et al. Intention to participate in a COVID-19 vaccine clinical trial and to get vaccinated against COVID-19 in France during the pandemic. Vaccine. 2020.
- DIA Global Forum. From COVID-19 Pandemic to War: Clinical Trial Industry Powers On Under Extreme Conditions. 2023.
- EMA. Reflection paper on risk based quality management in clinical trials (EMA/269011/2013). 2013.
- EMA. Guidance to sponsors on how to manage clinical trials during the COVID-19 pandemic (EMA/141885/2020). 2020.
- EMA. Advice to sponsors on managing the impact of the war in Ukraine on clinical trials. 2022.
- European Commission, EMA and HMA. Guidance on the management of clinical trials during the COVID-19 (Coronavirus) pandemic, version 5 (copy hosted by EJP RD). 2022.
- European Commission, HMA and EMA. Recommendation paper on decentralised elements in clinical trials, version 02 (supersedes December 2022). 2025.
- Faegre Drinker. FDA Updates Conduct of Clinical Trials During the COVID-19 Emergency (history of the 18 March 2020 FDA guidance and its updates). 2020.
- Fierce Biotech. Goldfinch Bio falls from the sky after failing to find a path forward for kidney treatments. 2023.
- Fortune. Pfizer pauses clinical trials in Russia. 2022.
- Freyr Solutions. FDA issues final guidance on conducting clinical trials with decentralized elements on 17th Sept 2024. 2024.
- Garner A et al. Evaluating the impact of NHS strikes on patient flow through emergency departments. Emergency Medicine Journal. 2026.
- GlobalData. 67.3% of clinical trials disrupted by COVID-19 are due to enrollment suspension. 2020.
- GlobalData. COVID-19 continues to disrupt clinical trials, with 69.9% of disruptions due to the suspension of enrolment. 2020.
- GlobalData. COVID-19 disrupted clinical trials with suspended enrollment more likely to resume. 2020.
- GOV.UK. Foreign travel advice.
- Haidich AB, Ioannidis JP. Determinants of patient recruitment in a multicenter clinical trials group: trends, seasonality and the effect of large studies. BMC Medical Research Methodology. 2001.
- Hussain R et al. Disruption of normal saline supply chain due to a disaster. Frontiers in Medicine. 2025.
- ICH. E8(R1) General Considerations for Clinical Studies, Step 4, adopted 6 October 2021. 2021.
- ICH. E6(R3) Good Clinical Practice, Step 4, adopted 6 January 2025. 2025.
- ICON plc. ICH GCP E6(R3): transformative updates make Good Clinical Practice better. 2025.
- IFRC. Türkiye Earthquake: IFRC Disaster Brief. 2023.
- Infosecurity Magazine. Ransomware Disrupts COVID-19 Medical Trials (reporting The New York Times). 2020.
- IQVIA Holdings. Q2 2020 earnings call transcript (The Motley Fool). 2020.
- ISID. About ProMED.
- Jenkins CR et al. Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study. European Respiratory Journal. 2012.
- Kalema AG et al. Building resilience when disaster strikes: adapting clinical trials in critical illness recovery. Annals of the American Thoracic Society. 2026.
- Kozlov M. NIH grant cuts will axe clinical trials abroad, and could leave thousands without care. Nature. 2025.
- Lab News (Phesi data). Ukraine conflict leaves a hole in clinical trials enrolment in region. 2022.
- Lab News (Phesi data). Putin invasion has seen loss of two out of three clinical investigator sites in Ukraine and Russia. 2023.
- Lafarga Previdi I et al. Lessons Learned: Community Engagement in Emergencies in Puerto Rico. Disaster Medicine and Public Health Preparedness. 2023.
- Mayo Clinic, In the Loop. In the Wake of Hurricane Maria, Mayo Clinic Clinical Trials Carry On in Puerto Rico. 2017.
- McDuffie R, Summerson J, Reilly P, Blackwell C, Goff D, Kimel AR, Crago L, Fonseca V. The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial and Hurricane Katrina: lessons for managing clinical trials during and after a natural disaster. Contemporary Clinical Trials. 2008.
- MedCity News. What the Great Resignation means for clinical research (OpenClinica survey; anecdotal). 2022.
- Médecins Sans Frontières. Ebola drug trial in Liberia halted. 2015.
- Médecins Sans Frontières. Sudan (country page, accessed October 2026). 2026.
- Medical Laboratory Observer. Labcorp Systems, Quest Diagnostics, Impacted by CrowdStrike-Related Outage. 2024.
- Medidata. COVID-19 and Clinical Trials: The Medidata Perspective, Release 6.0. 2020.
- Medidata. COVID-19 and Clinical Trials: The Medidata Perspective, Release 2.0 (cited in the research note as S1a). 2020.
- Meltzer GY et al. Aspirin and Preterm Birth Among Pregnant People With Increased Heat Exposure: Secondary Analysis of a Randomized Clinical Trial. JAMA Network Open. 2026.
- MHRA. Managing clinical trials during Coronavirus (COVID-19), first published 19 March 2020, last updated 16 November 2021. 2021.
- National Audit Office. Investigation: WannaCry cyber attack and the NHS. 2017.
- National Hurricane Center. Tropical Cyclone Report: Hurricane Katrina, 23 to 30 August 2005. 2005.
- National Hurricane Center. Tropical Cyclone Report: Hurricane Maria, 16 to 30 September 2017. 2017.
- News is my Business. Yale validates PRCCI's readiness after Hurricane María. 2018.
- NHS England. Synnovis cyber incident: public questions and answers. 2024.
- NHS England London. Update on cyber incident: clinical impact in south east London, Thursday 8 August. 2024.
- OncLive. Effects of Cancer Drug Shortages Linger as New Survey Results Show Impacts on Clinical Trials (NCCN survey). 2024.
- Outsourcing-Pharma. CROs report on Japan quake impact. 2011.
- Pharmaceutical Technology. Portage mulls company closure, pauses enrolment for lead clinical programme. 2024.
- Pharmaceutical Technology (GlobalData). Covid-19 pandemic disrupted more than 1,200 clinical trials: data. 2021.
- Pouncey A. Hurricane Katrina: What Have We Learned? Applied Clinical Trials. 2006.
- Premier Research. Seasonality: a factor for successful patient recruitment (anecdotal).
- Relias Media. When disaster strikes: In Katrina's wake, IRBs struggle to regroup.
- Shelford Group. Shelford CEOs statement on industrial action. 2023.
- Sidley Austin. US FDA's Adoption of ICH E6(R3) Good Clinical Practice: Key Takeaways for Sponsors and Investigators. 2025.
- Spectrum Science. Clinical Trial Experience (recruitment campaign data; anecdotal).
- Sun G et al. Crisis of the Clinical Trials Staff Attrition After the COVID-19 Pandemic. JCO Oncology Practice. 2023.
- The ASCO Post. New Survey Finds Cancer Drug Shortage Management Remains a Moving Target. 2024.
- The GDELT Project. Home page.
- The Pharma Letter. Global drugmakers refusing to test new drugs in Russia. 2022.
- The Transmitter. Biotech downturn hurts companies targeting autism-linked conditions. 2023.
- The White House (archived). Remarks by President Biden Providing an Update on Russia and Ukraine. 2022.
- Tully JL et al. Patient Care Technology Disruptions Associated With the CrowdStrike Outage. JAMA Network Open. 2025.
- UN OCHA ReliefWeb. ReliefWeb API documentation.
- Unger JM et al. Cancer Clinical Trial Participation at the 1-Year Anniversary of the Outbreak of the COVID-19 Pandemic. JAMA Network Open. 2021.
- Waterhouse DM et al. Early Impact of COVID-19 on the Conduct of Oncology Clinical Trials and Long-Term Opportunities for Transformation: Findings From an American Society of Clinical Oncology Survey. JCO Oncology Practice. 2020.
- Webster N, Vardy J, Wise-Rankovic A (INC Research). Enrollment Patterns: Implications for CNS Clinical Trials (ISCTM Autumn 2015 poster). 2015.
- WHO. Listings of WHO's response to COVID-19. 2020.
- WHO. Disease Outbreak News.
- WHO Regional Office for Europe. Türkiye earthquake: external situation report no. 2, 20 to 26 February. 2023.
- Williams RJ, Tse T, DiPiazza K, Zarin DA. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination. PLOS ONE. 2015.
- Wyatt S et al. Industrial action and emergency department attendances in England, 2022 to 2024: a retrospective multicentre causal mediation analysis. Journal of the Royal Society of Medicine. 2026.
- Yamamoto K et al. Loss of participation among evacuees aged 20 to 37 years in the disaster cohort study after the Great East Japan Earthquake. Scientific Reports. 2022.
Chapter 8 The numbers behind the planner: start-up times, screen failure, rates, and site variation
- Anisimov V, et al. Simulation of patient recruitment with gamma-distributed centre rates (arXiv 2411.17393). 2024.
- Ascot; CASRAI. Vendor web pages giving practice estimates for trial start-up in Türkiye.
- BioPharma Dive. Trials active in Ukraine at the invasion and permanent stops in the first year. 2023.
- BioSpectrum India. Clinical trial numbers in India drop drastically. 2013.
- Boehringer Ingelheim. EMPEROR-Reduced poster: empagliflozin according to background diuretic use in HFrEF (Verma). 2023.
- Brøgger-Mikkelsen M, et al. Recruitment performance of industry Phase III drug trials registered on ClinicalTrials.gov, 2012 to 2019. PLOS ONE. 2022.
- Chen, et al. Drop-out in 10,252 Phase III trials with results on ClinicalTrials.gov. British Journal of Clinical Pharmacology. 2025.
- CIDRAP, reporting JAMA Internal Medicine. NIH grant terminations disrupt hundreds of clinical trials, affecting more than 74,000 participants. 2025.
- DAPA-HF trial disposition, slide deck (to be verified against the NEJM 2019 primary paper). 2019.
- Fierce Biotech. Thousands of clinical trial sites impacted by war with Iran, Phesi report. 2026.
- Friends of Cancer Research. Data-driven insights: fast to start, slow to scale, US oncology trial start-up in a global context. 2026.
- Getz K, Tufts Center for the Study of Drug Development. Can recruitment and retention get any worse? Applied Clinical Trials. 2019.
- GlobalData, via Pharmaceutical Technology. Enrolment rates in Brazilian trials by number of sites, 2001 to 2018. Year not recorded in the note. 2018.
- GOV.UK. UK clinical research delivery key performance indicators, data to March 2026. 2026.
- Indian Journal of Pharmaceutical Education and Research. Article on the New Drugs and Clinical Trials Rules, 2019 (volume 53, issue 4s). 2019.
- Indian Pharma Post. Middle East disruption hits thousands of global clinical trials, Phesi warns. 2026.
- Infarma, with LongTaal data. Clinical trials in Poland, 2025 report. 2025.
- JAMA Network Open. Recruitment status changes among 888 ongoing trials with Ukrainian sites in the year after the invasion. 2023.
- Kemmler G, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs. Archives of General Psychiatry. 2005.
- KMR Group. Realistic recruitment expectations require disease and geographic considerations. Applied Clinical Trials. 2013.
- Lab News, reporting Phesi. Growth in oncology recruiting sites, 2019 to 2024. 2024.
- Letter on screened-not-randomised rates in the ILLUMINATE, SHINE, and SPARK COPD Phase III programmes (PubMed Central PMC5125986). 2016.
- medRxiv preprint. Phase III oncology trial sites recruiting on ClinicalTrials.gov in July 2024: 1,281 trials and 6,634 unique facilities. 2026.
- Minois N, et al. Poisson-gamma modelling of patient recruitment in IFM myeloma trials. Statistics in Medicine. 2017.
- Mondaq. Recent developments in the healthcare sector (Türkiye). Year not recorded in the note.
- Moore TJ, et al. Estimated costs of 225 pivotal trials supporting FDA approvals, 2015 to 2017. BMJ Open. 2020.
- PubMed Central article PMC8694703. Ethics committee approval times at 42 Indian sites in COVID-era trials. Year not recorded in the note.
- Redacción Médica, reporting Farmaindustria's Proyecto BEST. Se reduce en un mes el tiempo para iniciar un ensayo clínico en España, with later coverage in 2017 and 2019. 2016.
- Region Hovedstaden research portal. Screen failures and causes in inflammatory bowel disease randomised trials: a CRO analysis of 17 trials (Inflammatory Bowel Diseases). 2025.
- Sathian B, et al. Impact of COVID-19 on clinical trials, tabulating Medidata release 5.0 of 18 May 2020. Nepal Journal of Epidemiology. 2020.
- Sertkaya A, et al. Phase 3 per-study costs by therapeutic area, from Medidata data. Clinical Trials. 2016.
- Tata Memorial Centre. Screen failure in 15 randomised controlled trials (PubMed Central PMC9934872). 2023.
- Trial Agents. CTIS EU Phase 2 immunology timelines and factors (238 trials).
- Tufts Center for the Study of Drug Development. Pre-study visit to first patient in by site type, 5,296 sites in 105 trials. 2012.
- Tufts Center for the Study of Drug Development. Press release of 15 January 2013 on site enrolment performance, as reproduced by Fierce Biotech, Outsourcing-Pharma, and RAPS. 2013.
- Tufts Center for the Study of Drug Development, via GlobeNewswire. Press release on site identification and start-up cycle times, survey of 591 sponsors and CROs. 2018.
- UC San Diego, eScholarship. Screen failure across 269 oncology trials, 2013 to 2021. 2022.
- Urbas S, Sherlock C, Metcalfe P (AstraZeneca). Meta-analysis of recruitment across 20 oncology trials (Biostatistics 2020; arXiv 1910.07965). 2020.
- WCG Data Intelligence. Accelerating study activation: breaking down silos for start-up success (webinar slides). 2025.
Chapter 9 The forecasting model: how the sites-needed planner will work
- Anisimov VV. Using mixed Poisson models in patient recruitment in multicentre clinical trials (World Congress on Engineering, pp. 1046–1049). 2008.
- Anisimov VV. Statistical modeling of clinical trials (recruitment and randomization) (Communications in Statistics, Theory and Methods 40(19–20):3684–3699). 2011.
- Anisimov VV. Discussion paper on recruitment modelling in Contemporary Clinical Trials (title not recorded in the note; Glasgow eprint 137911). 2016.
- Anisimov VV, Austin MD. Modeling restricted enrollment and optimal cost-efficient design in multicenter clinical trials (arXiv:2212.12930). 2022.
- Anisimov VV, Mijoule G, Turchetta M, Savy N. Modelling and forecasting patient recruitment in multicentre clinical trials with patients' dropout (arXiv:2202.06779; title as recorded in the note). 2022.
- Bakhshi A. MSc thesis, University of Glasgow: negative binomial fits to per-centre recruitment totals in 18 completed trials (title as catalogued not recorded in the note). 2011.
- Bakhshi A, Senn S, Phillips A. Some issues in predicting patient recruitment in multi-centre clinical trials (Statistics in Medicine 32(30):5458–5468). 2013.
- Barnard KD, Dent L, Cook A. A systematic review of models to predict recruitment to multicentre clinical trials (BMC Medical Research Methodology 10:63). 2010.
- Bütikofer L, Haynes A. accrualPlot 1.0.10, R package manual (CRAN).
- Carter RE. Application of stochastic processes to participant recruitment in clinical trials (Controlled Clinical Trials 25(5):429–436). 2004.
- Carter RE, Sonne SC, Brady KT. Practical considerations for estimating clinical trial accrual periods: application to a multi-center effectiveness study (BMC Medical Research Methodology 5:11). 2005.
- CRAN contributors. fahb, R package manual: hierarchical Poisson accrual with log-normal site rates.
- Deng Y, Zhang X, Long Q. Bayesian modeling and prediction of accrual in multi-regional clinical trials (Statistical Methods in Medical Research 26(2):752–765). 2017.
- Gajewski BJ, Jiang Y, and contributors. accrual 1.4, R package source, accrual.n.inform.R (CRAN, GPL-2; paper Jiang et al., Trials 17:336, 2016). 2016.
- Gajewski BJ, Simon SD, Carlson SE. Predicting accrual in clinical trials with Bayesian posterior predictive distributions (Statistics in Medicine 27(13):2328–2340). 2008.
- Hickey GL, and colleagues. goldilocks 1.0.0, R package manual (CRAN, GPL-3).
- Jiang Y, Simon S, Mayo MS, Gajewski BJ. Modeling and validating Bayesian accrual models on clinical data and simulations using adaptive priors (Statistics in Medicine 34(4):613–629). 2015.
- JMP Statistical Discovery. JMP Clinical user guide: Patient Recruitment.
- Lan Y, Tang G, Heitjan DF. Statistical modeling and prediction of clinical trial recruitment (Statistics in Medicine 38(6):945–955). 2019.
- Liu J, Wick J, Jiang Y, Mayo M, Gajewski B. Bayesian accrual modeling and prediction in multicenter clinical trials with varying center activation times (Pharmaceutical Statistics 19(5):692–709). 2020.
- Lu K. eventPred 0.3.1, R package manual (CRAN).
- Merck. simtrial, R package (CRAN): piecewise-exponential enrolment generator.
- Mijoule G, Minois N, Anisimov VV, Savy N. Springer chapter modelling screening loss with centre-specific beta probabilities inside a cost model (DOI 10.1007/978-1-4939-2104-1_36; title not recorded in the note). 2014.
- Minois N, Savy S, Lauwers-Cances V, Andrieu S, Savy N. How to deal with the Poisson-gamma model to forecast patients' recruitment in clinical trials when there are pauses in recruitment dynamic? (Contemporary Clinical Trials Communications, PMC5936707). 2017.
- Mountain R, Sherlock C. Recruitment prediction for multi-centre clinical trials based on a hierarchical Poisson-gamma model: asymptotic analysis and improved intervals (Biometrics 78(2):636–648; arXiv:1912.09790). 2022.
- Ninh A, Hunt, Nguyen. Estimation of patient recruitment using summary data aggregated across trials (INFORMS Journal on Computing 2024.0780; R package pgc, MIT licence). 2024.
- Saha D, Anisimov V, Fedorov V, Heiberger R. useR 2010 slides on GSK's R and RExcel recruitment package (title not recorded in the note). 2010.
- Shipes VB, Meinzer C, Wolf BJ, Li H, Carpenter MJ, Kamel H, Martin RH. Designing a phase-III time-to-event clinical trial using a modified sample size formula and Poisson-Gamma model for subject accrual that accounts for the lag in site initiation using the PERT distribution (Statistics in Medicine 42(30):5694–5707). 2023.
- Turchetta M, and colleagues. A time-dependent Poisson-Gamma model for recruitment forecasting in multicenter studies (Statistics in Medicine 42(23):4193–4206; arXiv:2301.03710). 2023.
- Urbas S. ct-recuitment-prediction: R code for interim recruitment prediction (MLE.R, BMA.R, data_sim.R, Delay_process). 2022.
- Zhang X, Long Q. Stochastic modeling and prediction for accrual in clinical trials (Statistics in Medicine 29(6):649–658). 2010.
- Zhong Y, Xing Y, Yu Y, Wang J. Enrollment forecast for clinical trials at the portfolio planning phase based on site-level historical data (Pharmaceutical Statistics 23(2):151–167; arXiv:2301.01351; companion paper Yu et al., Therapeutic Innovation and Regulatory Science 58(1):42–52). 2024.
Review note 01 Quality tolerance limits: which trial-level parameters matter most
- ACRO. 2025 RBQM Landscape Summary Report (2024 data). June. 2025.
- ACRO and TransCelerate. Acceptable Ranges for Clinical Trials: Insights from ICH E6(R3). Version 1.0, 11 February. 2025.
- Akl EA, Briel M, You JJ, et al. Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 2012;344:e2809. 2012.
- Bhagat R, Bojarski L, Chevalier S, et al. Quality Tolerance Limits: Framework for Successful Implementation in Clinical Development. Ther Innov Regul Sci. 2021;55(2):251-261. doi:10.1007/s43441-020-00209-0. 2021.
- de Viron S, Blais F. Quality Tolerance Limits: Why Breaches Happen Early and How to Act Fast. Applied Clinical Trials, 9 March. 2026.
- de Viron S, Young S. Quality Tolerance Limits: A Review of Industry Trends. Applied Clinical Trials, 2 March. 2023.
- Fergusson D, Aaron SD, Guyatt G, Hébert P. Post-randomisation exclusions: the intention to treat principle and excluding patients from analysis. BMJ. 2002;325:652. 2002.
- Getz K, Smith Z, Jain A, Krauss R. Benchmarking Protocol Deviations and Their Variation by Major Disease Categories. Ther Innov Regul Sci. 2022;56(4):632-636. doi:10.1007/s43441-022-00401-4. 2022.
- ICH. Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice E6(R2). 2016.
- Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355-1360. 2012.
- Makowski M, Bhagat R, Chevalier S, et al. Historical Benchmarks for Quality Tolerance Limits Parameters in Clinical Trials. Ther Innov Regul Sci. 2021;55(6):1265-1273. doi:10.1007/s43441-021-00335-3. 2021.
- Stansbury N, et al. Risk-Based Quality Management: A Case for Centralized Monitoring. Ther Innov Regul Sci. doi:10.1007/s43441-024-00719-1. 2024.
- TransCelerate BioPharma. Member Companies Using the QTL Framework Report Benefits (implementation experiences page; adoption figure from 2021). 2021.
- US FDA. Bioresearch Monitoring (BIMO) Fiscal Year 2024 Metrics. 2024.
- Walsh M, Srinathan SK, McAuley DF, et al. The statistical significance of randomized controlled trial results is frequently fragile: a case for a Fragility Index. J Clin Epidemiol. 2014;67(6):622-628. 2014.
- Wolfs M, Bojarski L, Young S, et al. Quality Tolerance Limits' Place in the Quality Management System and Link to the Statistical Trial Design: Case Studies and Recommendations from Early Adopters. Ther Innov Regul Sci. 2023;57(4):839-848. doi:10.1007/s43441-023-00504-6. 2023.
- Yelland LN, et al. Prevalence and reporting of recruitment, randomisation and treatment errors in clinical trials: a systematic review. Clin Trials. 2018.
Review note 02 Operational KPIs that predict trial outcome
- A machine learning approach for recruitment prediction in clinical trial design. arXiv:2111.07407. 2021.
- Applied Clinical Trials article on whether to extrapolate site enrolment from past performance (Phesi analysis; vendor view, read via search summary only).
- Getz K. Can recruitment and retention get any worse? Applied Clinical Trials, 1 December 2019. 2019.
- Hoy K, Gerds A, Chan J, et al. First accrual within 70 days of opening predicts overall trial accrual success (work in progress poster). Case Comprehensive Cancer Center, AACI Clinical Research Innovation meeting. 2023.
- Imperial College London Joint Research Office. NIHR benchmark: Performance in Initiating and Delivering clinical research (70-day benchmark).
- Lamberti MJ, Wilkinson M, Harper B, Morgan C, Getz K. Assessing study start-up practices, performance, and perceptions among sponsors and contract research organizations. Therapeutic Innovation & Regulatory Science 2018;52(5):572–578. 2018.
- Site-specific factors associated with clinical trial recruitment efficiency in general practice settings: a comparative descriptive analysis. PubMed Central PMC9985191.
- Sullivan LB. MCC metric of the month: on-time site initiation. Applied Clinical Trials, 15 November. 2013.
- Tang C, Sherman SI, Price M, et al. Clinical trial characteristics and barriers to participant accrual: the MD Anderson Cancer Center experience over 30 years. Clinical Cancer Research 2017;23(6):1414–1421. doi:10.1158/1078-0432.CCR-16-2439. 2017.
- TransCelerate BioPharma. Risk-based monitoring interactive guide: risk indicators and thresholds.
Review note 03 What works when a recruitment or retention metric goes red
- Brueton VC, Tierney JF, Stenning S, et al. Strategies to improve retention in randomised trials: a Cochrane systematic review and meta-analysis. BMJ Open. 2014.
- Brunsdon et al. What are the most important unanswered research questions in trial retention? The PRioRiTy II study. Trials. 2019.
- Giguere AM, Labrecque M, Borduas F, Rouleau M. Effectiveness of monetary incentives to recruit family physicians as study subjects: a randomized controlled trial. BMC Research Notes. 2015.
- Jones R, Jones RO, McCowan C, et al. The external validity of published randomized controlled trials in primary care. BMC Family Practice 2009;10:5. 2009.
- Koog YH, et al. External Validity of Knee Osteoarthritis Clinical Trials: A Systematic Review. Archives of Rheumatology. 2015.
- Lewis R, Todd R, Newton M, et al. The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial. Trials. 2020.
- Miyata BL, Tafuto B, Jose N. Methods and perceptions of success for patient recruitment in decentralized clinical studies. Journal of Clinical and Translational Science. 2023.
- Parekh et al. Audit of screen failure in 15 randomised studies from a low and middle-income country. ecancermedicalscience. 2022.
- Parker A, Arundel C, Clark L, et al. Undertaking Studies Within A Trial to evaluate recruitment and retention strategies for randomised controlled trials: lessons learnt from the PROMETHEUS research programme. Health Technology Assessment 2024;28(2). 2024.
- Rogers A, De Paoli G, Subbarayan S, et al. A systematic review of methods used to conduct decentralised clinical trials. British Journal of Clinical Pharmacology. 2022.
- Treweek S, et al. Methods to improve recruitment to randomised controlled trials: Cochrane systematic review and meta-analysis. BMJ Open 2013;3:e002360. 2013.
- Tufts Center for the Study of Drug Development. Protocol amendments improve elements of clinical trial feasibility, but at high economic and cycle time cost (press release, 14 January 2016, via BioSpace). 2016.
- Worldwide Clinical Trials. Unique 4-step approach limits high screen failure in Alzheimer's disease research, part 1 (industry blog, 2017). 2017.
Added while building the site
- BOE. Real Decreto 463/2020, de 14 de marzo, por el que se declara el estado de alarma para la gestión de la situación de crisis sanitaria ocasionada por el COVID-19. Boletín Oficial del Estado 67. 2020.
- Gazzetta Ufficiale. Decreto-legge 23 febbraio 2020, n. 6: misure urgenti in materia di contenimento e gestione dell’emergenza epidemiologica da COVID-19. Gazzetta Ufficiale della Repubblica Italiana, Serie Generale 45. 2020.
- Khan MS, Jamil A, Shakoor M, et al. Patient Enrollment for Cardiovascular Clinical Trials in the United States. JAMA Cardiology 10(3):298-300. 2025.
- McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine 381:1995-2008. 2019.
- Packer M, Anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. New England Journal of Medicine 383:1413-1424. 2020.
- Patel VR, Liu M, Jena AB. Clinical Trials Affected by Research Grant Terminations at the National Institutes of Health. JAMA Internal Medicine. 2025.
- Prime Minister’s Office. Prime Minister’s address to the nation on coronavirus: 23 March 2020. GOV.UK. 2020.
- Spiegelhalter DJ. Funnel plots for comparing institutional performance. Statistics in Medicine 24(8):1185-1202. 2005.
- The Lancet. India’s COVID-19 emergency. The Lancet 397(10286):1683. 2021.
- Tian H, Liu Y, Li Y, et al. An investigation of transmission control measures during the first 50 days of the COVID-19 epidemic in China. Science 368(6491):638-642. 2020.
- TransCelerate BioPharma. Risk Assessment and Categorization Tool (RACT), in The TransCelerate Model Approach. Risk-based monitoring interactive guide. 2013.
- UN Special Advisers. Joint statement by the UN Special Advisers on the Prevention of Genocide and on the Responsibility to Protect on the situation in northeast Syria. United Nations press release, New York, 15 October 2019. 2019.
- UNHCR. Ukraine refugee situation: operational data portal. UNHCR. 2022.
- US Congress. Food and Drug Omnibus Reform Act of 2022 (FDORA), in the Consolidated Appropriations Act, 2023. Public Law 117-328, Division FF, Title III. 2022.